[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3376
1. Anderson CA, Curzon ME, Van Loveren C, Tatsi C, Duggal MS: Sucrose and dental caries: a review of the evidence. Obes Rev; 2009 Mar;10 Suppl 1:41-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sucrose and dental caries: a review of the evidence.
  • The aim of this study was to conduct a review of the literature to assess the relationship between quantity and pattern of sucrose use and dental caries.
  • Using hand and electronic methods (MEDLINE, EMBASE) the literature was searched for epidemiological papers concerning any relationship of sugars and dental caries published since 1856.
  • Superficial hand searching was carried out between 1856 and 1940, detailed hand searching 1940-1966 and electronic 1966-2007.
  • Selection criteria were set based on, but not confined to, Cochran style standards.
  • Investigations were categorized as A, fulfilling all criteria; B1, relevant fulfilling 19 of 23 criteria; B2, relevant but fulfilling only between 12 and 18 of the selection criteria; and C, all other papers.
  • There were 95 papers meeting most (more than 12) or all of the selected criteria.
  • Only 1 paper was graded A; 31 as B1.
  • There were in addition some 65 as B2 and all the rest as C, which were discarded.
  • There were a wide variety of study designs and those graded A or B1 comprised 23 ecological cross-sectional, 7 cohort and 2 case control studies.
  • Summary results showed that 6 papers found a positive, significant relationship of sugar quantity to dental caries, 19 of 31 studies reported a significant relationship of sugar frequency of use to dental caries.
  • The balance of studies does not demonstrate a relationship between sugar quantity, but a moderately significant relationship of sugar frequency to dental caries.
  • [MeSH-major] Dental Caries / etiology. Dietary Sucrose / adverse effects
  • [MeSH-minor] Humans

  • MedlinePlus Health Information. consumer health - Tooth Decay.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19207535.001).
  • [ISSN] 1467-789X
  • [Journal-full-title] Obesity reviews : an official journal of the International Association for the Study of Obesity
  • [ISO-abbreviation] Obes Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dietary Sucrose
  • [Number-of-references] 44
  •  go-up   go-down


2. Wang SD, Yuan L, Jiang Y, Li XQ, Wang XZ: [Myocardial protective effect of Shenfu injection in patients undergoing valve replacement]. Zhonghua Yi Xue Za Zhi; 2007 Sep 4;87(33):2316-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myocardial protective effect of Shenfu injection in patients undergoing valve replacement].
  • OBJECTIVE: To investigate the myocardial protective effect of Shenfu injection in patients undergoing valve replacement.
  • METHODS: Forty patients undergoing valve replacement surgery under cardio-pulmonary bypass (CPB) were randomly divided into two equal groups: group C (control group, given with 4:1 blood containing cardioplegic liquid during the CPB) and group SF (Shenfu injection, receiving the blood containing cardioplegic liquid with 20 ml/L of Shenfu injection additionally).
  • Blood samples were withdrawn from the central vein before operation, 30 minutes after aorta declamping, and 4, 12, and 24 hours after CPB, to test the serum cardiac troponin I (cTnI), creatine phosphokinase (CK), and creatine phosphokinase isoenzyme (CK-MB).
  • RESULTS: The CK, CK-MB, and cTnI level were normal before operation and there were no significant differences in these indexes between the two groups.
  • 30 minutes after aorta declamping, the CK, CK-MB, and cTnI levels were higher than those before operation in both groups (P < 0.05, P < 0.
  • 01), and the higher levels remained to 24 hours after CPB.
  • 24 hours after CPB, the CK level of the group SF was significantly lower than that of the group C (P < 0.05), and 30 minutes after aorta declamping to 24 h after CPB, the CK-MB and cTnI levels were lower in the group SF compared with the group C (all P < 0. 05).
  • CONCLUSION: Shenfu injection decreases the level of CK, CK-MB and cTnI, and reduces the myocardial injury.
  • [MeSH-major] Cardiomyopathies / prevention & control. Drugs, Chinese Herbal / therapeutic use. Heart Valve Prosthesis Implantation / methods
  • [MeSH-minor] Adult. Aged. Cardioplegic Solutions / administration & dosage. Cardiopulmonary Bypass. Cardiotonic Agents / administration & dosage. Cardiotonic Agents / therapeutic use. Creatine Kinase / blood. Creatine Kinase, MB Form / blood. Female. Heart Arrest, Induced / methods. Humans. Male. Middle Aged. Troponin I / blood

  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18036292.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cardioplegic Solutions; 0 / Cardiotonic Agents; 0 / Drugs, Chinese Herbal; 0 / Shen-Fu; 0 / Troponin I; EC 2.7.3.2 / Creatine Kinase; EC 2.7.3.2 / Creatine Kinase, MB Form
  •  go-up   go-down


3. Bashashati A, Nouredin B, Ward RK, Lawrence P, Birch GE: Effect of eye-blinks on a self-paced brain interface design. Clin Neurophysiol; 2007 Jul;118(7):1639-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of eye-blinks on a self-paced brain interface design.
  • OBJECTIVE: To test the performance of an EEG-based self-paced brain interface when data contaminated with eye-blink artefacts are included in the evaluation.
  • METHODS: Two different designs of a self-paced brain interface (the low frequency-asynchronous switch design, LF-ASD) are evaluated and compared using offline data from eight subjects.
  • The true positive rates of the two designs are compared for three cases: (a) data containing eye-blink artefacts are excluded from the input;.
  • (b) all data, including eye-blinks, are included as input but the output decisions are inactivated during eye-blink artefacts;.
  • (c) all the data, including eye-blinks, are included as input and the output decisions are reported in all times including during eye-blink artefacts.
  • RESULTS: The true positive rates of one design of the LF-ASD (LF-ASD-V5) for case (c) and of another design (LF-ASD-V4) for case (b) are 40.5% and 42.4%, respectively, for false positive rates of 1%.
  • CONCLUSIONS: The true positive rates of LF-ASD-V5 when eye-blinks are included in the analysis deteriorate slightly compared to when the output during eye-blink artefacts is inactivated in LF-ASD-V4.
  • SIGNIFICANCE: LF-ASD-V5 allows the device to be functional at all times and can handle artefacts better than LF-ASD-V4.
  • If a slight decrease in true positive rates is acceptable, no further devices are needed to record the electro-oculogram (EOG) for detecting eye-blinks.
  • [MeSH-major] Artifacts. Blinking / physiology. Brain / physiology. Electroencephalography / instrumentation
  • [MeSH-minor] Adult. Data Interpretation, Statistical. Electrooculography. False Positive Reactions. Female. Fingers / physiology. Humans. Male. Middle Aged. Movement / physiology. ROC Curve. Spinal Cord Injuries / physiopathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17466588.001).
  • [ISSN] 1388-2457
  • [Journal-full-title] Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  • [ISO-abbreviation] Clin Neurophysiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


Advertisement
4. Tommasi F, Paciolla C, de Pinto MC, De Gara L: Effects of storage temperature on viability, germination and antioxidant metabolism in Ginkgo biloba L. seeds. Plant Physiol Biochem; 2006 May-Jun;44(5-6):359-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At 25 degrees C a significant decrease in the ASC content in the embryos was evident, whereas it remained more stable in the endosperm.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889978.001).
  • [ISSN] 0981-9428
  • [Journal-full-title] Plant physiology and biochemistry : PPB
  • [ISO-abbreviation] Plant Physiol. Biochem.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antioxidants; EC 1.- / Oxidoreductases; EC 1.11.1.- / Peroxidases; EC 1.11.1.11 / Ascorbate Peroxidases; EC 1.11.1.6 / Catalase; EC 1.6.- / NADH, NADPH Oxidoreductases; EC 1.6.5.4 / monodehydroascorbate reductase (NADH); EC 1.8.1.7 / Glutathione Reductase; EC 1.8.5.1 / glutathione dehydrogenase (ascorbate); GAN16C9B8O / Glutathione; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


5. Troughton RW, Richards AM: Outpatient monitoring and treatment of chronic heart failure guided by amino-terminal pro-B-type natriuretic peptide measurement. Am J Cardiol; 2008 Feb 4;101(3A):72-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient monitoring and treatment of chronic heart failure guided by amino-terminal pro-B-type natriuretic peptide measurement.
  • Amino-terminal pro-B-type natriuretic peptide (NT-proBNP) is a strong and independent prognostic marker in patients across the spectrum of heart failure (HF) stages, including patients managed in the outpatient setting.

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18243863.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  • [Number-of-references] 37
  •  go-up   go-down


6. Baptista MJ, Rocha G, Clemente F, Azevedo LF, Tibboel D, Leite-Moreira AF, Guimarães H, Areias JC, Correia-Pinto J: N-terminal-pro-B type natriuretic peptide as a useful tool to evaluate pulmonary hypertension and cardiac function in CDH infants. Neonatology; 2008;94(1):22-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-terminal-pro-B type natriuretic peptide as a useful tool to evaluate pulmonary hypertension and cardiac function in CDH infants.
  • Plasmatic N-terminal-pro-B type natriuretic peptide (NT-proBNP) might be useful in diagnosis and management of PH in newborns, although its interest in CDH infants remains to be defined.
  • [MeSH-major] Heart / physiopathology. Hernia, Diaphragmatic / physiopathology. Hernias, Diaphragmatic, Congenital. Hypertension, Pulmonary / blood. Hypertension, Pulmonary / diagnosis. Natriuretic Peptide, Brain / blood. Peptide Fragments / blood

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 18160811.001).
  • [ISSN] 1661-7819
  • [Journal-full-title] Neonatology
  • [ISO-abbreviation] Neonatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


7. Thaman R, Esteban MT, Barnes S, Gimeno JR, Mist B, Murphy R, Collinson PO, McKenna WJ, Elliott PM: Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol; 2006 Aug 15;98(4):515-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy.
  • The aim of this study was to determine the usefulness of N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) as a marker of exercise performance in HC.
  • Plasma NT-pro-BNP was measured in 171 consecutive patients (mean age 46 +/- 18 years) who underwent echocardiography and cardiopulmonary exercise testing.
  • The mean log NT-pro-BNP was 2.79 +/- 0.5; log NT-pro-BNP levels were higher in women patients (p = 0.001) and patients with chest pain (p = 0.010), in New York Heart Association class > or = II (p = 0.009), with atrial fibrillation (p < 0.001), with systolic impairment (p = 0.025), and with LV outflow tract obstructions (p < 0.0001).
  • NT-pro-BNP levels were also correlated with maximal wall thickness (r = 0.335, p < 0.0001), left atrial size (r = 0.206, p = 0.007), and the mitral Doppler E/A ratio (r = 0.197, p = 0.012).
  • There were inverse correlations between percent VO2max and NT-pro-BNP (r = -0.352, p = 0.001), LV end-systolic cavity size (r = -0.182, p = 0.031), and left atrial size (r = -0.251, p = 0.003).
  • On multivariate analysis, only NT-pro-BNP was correlated with percent VO2max.
  • A NT-pro-BNP level of 316 ng/L had 78% sensitivity and 44% specificity (area under the curve 0.616) for predicting percent VO2max < 80%.
  • In conclusion, NT-pro-BNP levels correlate with peak oxygen consumption in HC and are more predictive of functional impairment than other conventional markers of disease severity.

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • Genetic Alliance. consumer health - Hypertrophic Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16893708.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


8. Thummes K, Schäfer J, Kämpfer P, Jäckel U: Thermophilic methanogenic Archaea in compost material: occurrence, persistence and possible mechanisms for their distribution to other environments. Syst Appl Microbiol; 2007 Dec;30(8):634-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thermophilic methanogenic Archaea in compost material: occurrence, persistence and possible mechanisms for their distribution to other environments.
  • Since compost is widely used as soil amendment and the fact that during the processing of compost material high amounts of microorganisms are released into the air, we investigated whether compost may act as a carrier for thermophilic methanogens to temperate soils.
  • All eight investigated compost materials showed a clear methane production potential between 0.01 and 0.98 micromol CH(4) g dw(-1)h(-1) at 50 degrees C.
  • Single strand conformation polymorphism (SSCP) and cloning analysis indicated the presence of Methanosarcina thermophila, Methanoculleus thermophilus, and Methanobacterium formicicum.
  • Bioaerosols collected during the turning of a compost pile showed both a highly similar SSCP profile compared to the corresponding compost material and clear methane production during anoxic incubation in selective medium at 50 degrees C.
  • Both observations indicated a considerable release of thermophilic methanogens into the air.
  • To analyse the persistence of compost-borne thermophilic methanogens in temperate oxic soils, we therefore studied their potential activity in compost and compost/soil mixtures, which was brought to a meadow soil, as well as in an agricultural soil fertilised with compost.
  • After 24h anoxic incubation at 50 degrees C, all samples containing compost showed a clear methanogenic activity, even 1 year after application.
  • In combination with the in vitro observed resilience of the compost-borne methanogens against desiccation and UV radiation we assume that compost material acts as an effective carrier for the distribution of thermophilic methanogens by fertilisation and wind.
  • [MeSH-major] Methane / biosynthesis. Methanobacterium / isolation & purification. Methanomicrobiaceae / isolation & purification. Methanosarcina / isolation & purification. Soil Microbiology
  • [MeSH-minor] DNA, Bacterial / genetics. Desiccation. Hot Temperature. Molecular Sequence Data. Polymorphism, Single-Stranded Conformational. Sequence Analysis, DNA. Ultraviolet Rays

  • Hazardous Substances Data Bank. METHANE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988815.001).
  • [ISSN] 0723-2020
  • [Journal-full-title] Systematic and applied microbiology
  • [ISO-abbreviation] Syst. Appl. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AM747292/ AM747293/ AM747294/ AM747295/ AM747296/ AM747297/ AM747298/ AM747299/ AM747300/ AM747301
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Bacterial; OP0UW79H66 / Methane
  •  go-up   go-down


9. Victor S, Marson AG, Appleton RE, Beirne M, Weindling AM: Relationship between blood pressure, cerebral electrical activity, cerebral fractional oxygen extraction, and peripheral blood flow in very low birth weight newborn infants. Pediatr Res; 2006 Feb;59(2):314-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between blood pressure, cerebral electrical activity, cerebral fractional oxygen extraction, and peripheral blood flow in very low birth weight newborn infants.
  • There is uncertainty about the level of systemic blood pressure required to maintain adequate cerebral oxygen delivery and organ integrity.
  • This prospective, observational study on 35 very low birth weight infants aimed to determine the mean blood pressure (MBP) below which cerebral electrical activity, peripheral blood flow (PBF), and cerebral fractional oxygen extraction (CFOE) are abnormal.
  • Digital EEG, recorded every day on the first 4 d after birth, were analyzed a) by automatic spectral analysis, b) by manual measurement of interburst interval, and c) qualitatively.
  • CFOE and PBF measurements were performed using near-infrared spectroscopy and venous occlusion.
  • MBP was measured using arterial catheters.
  • The median (range) of MBP recorded was 32 mm Hg (16-46).
  • The EEG became abnormal at MBP levels below 23 mm Hg: a) the relative power of the delta (0.5-3.5 Hz) frequency band was decreased, b) interburst intervals were prolonged, and c) all four qualitatively abnormal EEG (low amplitude and prolonged interburst intervals) from four different patients were recorded below this MBP level.
  • The only abnormally high CFOE was measured at MBP of 20 mm Hg.
  • PBF decreased at MBP levels between 23 and 33 mm Hg.
  • None of the infants in this study developed cystic periventricular leukomalacia.
  • One infant (MBP, 22 mm Hg) developed ventricular dilatation after intraventricular hemorrhage.
  • The EEG and CFOE remained normal at MBP levels above 23 mm Hg.
  • It would appear that cerebral perfusion is probably maintained at MBP levels above 23 mm Hg.
  • [MeSH-major] Blood Pressure. Brain / physiology. Cerebrovascular Circulation. Infant, Very Low Birth Weight / physiology. Oxygen / metabolism
  • [MeSH-minor] Electroencephalography. Fourier Analysis. Humans. Infant, Newborn

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16439599.001).
  • [ISSN] 0031-3998
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


10. Khoury HJ, Loberiza FR Jr, Ringdén O, Barrett AJ, Bolwell BJ, Cahn JY, Champlin RE, Gale RP, Hale GA, Urbano-Ispizua A, Martino R, McCarthy PL, Tiberghien P, Verdonck LF, Horowitz MM: Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood; 2006 Feb 15;107(4):1712-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation.
  • Granulocyte colony-stimulating factor (G-CSF) is often administered after hematopoietic-cell transplantation (HCT) to accelerate neutrophil recovery, but it is unclear what impact G-CSF has on long-term transplantation outcomes.
  • We analyzed within the database of the Center for International Blood and Marrow Transplant Research the impact of giving posttransplantation G-CSF on the outcomes of allogeneic HCT for acute myelogenous leukemia and chronic myelogenous leukemia in 2719 patients who underwent transplantation between 1995 and 2000.
  • Outcomes were compared between patients receiving or not receiving G-CSF within 7 days of HCT according to graft type.
  • Probabilities of acute and chronic graft-versus-host disease (GVHD), leukemia-free survival (LFS), and overall survival were similar whether or not G-CSF was given.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2003 Jul;32(2):217-23 [12838288.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(8):771-5 [14520420.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):416-23 [14691124.001]
  • [Cites] Exp Hematol. 1989 Nov;17(10):1047-50 [2478381.001]
  • [Cites] Lancet. 1990 Dec 8;336(8728):1417-20 [1978880.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2514-21 [11290617.001]
  • [Cites] Blood. 1995 Dec 15;86(12):4422-9 [8541530.001]
  • [Cites] Blood. 1997 Jul 1;90(1):453-63 [9207483.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4872-80 [15520055.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):949-54 [7581096.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2269-74 [10733495.001]
  • [Cites] Blood. 1992 Mar 1;79(5):1359-65 [1536959.001]
  • (PMID = 16239431.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  • [Other-IDs] NLM/ PMC1895414
  •  go-up   go-down


11. Boonthimat C, Thongnoppakhun W, Auewarakul CU: Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations. Haematologica; 2008 Oct;93(10):1565-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations.
  • NPM1 mutations were investigated in 400 Southeast Asian leukemia patients and were detectable in 105 cases (26.25%) of acute myeloid leukemia but in no cases of acute lymphoid leukemia or chronic myeloid leukemia.
  • Older age, high white blood cell and platelet counts, normal cytogenetics, and CD34-negativity were associated with NPM1 mutation.
  • FLT3 mutation was more frequent in mutant NPM1 than wild-type cases (56.8% vs. 25.6%) whereas RAS and AML1 mutations were rarely found.
  • We conclude that: i) NPM1 mutation represents a common genetic hallmark in Southeast Asian acute myeloid leukemia with a normal karyotype;.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. Leukemia, Myeloid, Acute / metabolism. Leukemia, Myeloid, Acute / pathology. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. fms-Like Tyrosine Kinase 3 / genetics. fms-Like Tyrosine Kinase 3 / metabolism

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18641025.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


12. Mallol-Mesnard N, Menegaux F, Auvrignon A, Auclerc MF, Bertrand Y, Nelken B, Robert A, Michel G, Margueritte G, Perel Y, Méchinaud F, Bordigoni P, Leverger G, Baruchel A, Hémon D, Clavel J: Vaccination and the risk of childhood acute leukaemia: the ESCALE study (SFCE). Int J Epidemiol; 2007 Feb;36(1):110-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccination and the risk of childhood acute leukaemia: the ESCALE study (SFCE).
  • BACKGROUND: In 2002, a poster alerted the French health authorities to the possibility that the risk of childhood leukaemia might be increased by hepatitis B vaccination.
  • Elucidating the role of vaccination in the aetiology of childhood acute leukaemia (AL) was therefore included in the objectives of an ongoing national study.
  • METHODS: The ESCALE study was a French national population-based case-control study conducted in France in 2003 and 2004 in order to investigate the role of infectious, environmental and genetic factors in four childhood neoplastic diseases (leukaemia, lymphoma, neuroblastoma and brain tumour).
  • In a specific standardized telephone interview, which was the same for both the cases and controls, each mother was asked to read out her child's complete vaccination record.
  • RESULTS: No association between vaccination and the risk of childhood AL: acute lymphoblastic leukaemia or acute myeloblastic leukaemia was observed.
  • No relationship between the risk of leukaemia and the type of vaccine, number of doses of each vaccine, total number of injections, total number of vaccine doses or number of early vaccinations was evidenced.
  • CONCLUSION: The study did not show any evidence of a role of vaccination in the aetiology of childhood leukaemia.
  • [MeSH-major] Hepatitis B Vaccines / adverse effects. Leukemia / immunology
  • [MeSH-minor] Adolescent. Age Distribution. Case-Control Studies. Child. Child, Preschool. Drug Administration Schedule. Female. France / epidemiology. Humans. Infant. Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / virology. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology. Risk Assessment / methods. Sex Distribution. Vaccination / adverse effects

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Prev. 2004 Apr;13(2):97-103 [15100575.001]
  • [Cites] Int J Epidemiol. 2005 Oct;34(5):1100-9 [15951359.001]
  • [Cites] BMJ. 2005 Jun 4;330(7503):1294 [15849205.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):175-8 [10487630.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1483-9 [10424755.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):585-90 [10408870.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):234-40 [10638995.001]
  • [Cites] Br J Cancer. 1997;76(9):1241-7 [9365177.001]
  • [Cites] Am J Epidemiol. 1986 Oct;124(4):590-4 [3463201.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):139-45 [14710221.001]
  • [Cites] Arch Pediatr. 2003 May;10(5):403-9 [12878332.001]
  • [Cites] Paediatr Perinat Epidemiol. 2002 Apr;16(2):154-65 [12060313.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1064-9 [11953850.001]
  • [Cites] Bull World Health Organ. 1999;77(3):224-9 [10212512.001]
  • (PMID = 17227780.001).
  • [ISSN] 0300-5771
  • [Journal-full-title] International journal of epidemiology
  • [ISO-abbreviation] Int J Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  • [Other-IDs] NLM/ HALMS168385; NLM/ PMC2292812
  •  go-up   go-down


13. Szczepanek J, Pogorzala M, Konatkowska B, Juraszewska E, Badowska W, Olejnik I, Kuzmicz M, Stanczak E, Malinowska I, Stefaniak J, Sobol G, Szczepanski T, Czyzewski K, Wysocki M, Styczynski J: Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia. Anticancer Res; 2010 Jun;30(6):2119-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia.
  • The objective of this study was the analysis of the ex vivo activity of bortezomib in paediatric acute lymphoblastic leukaemia (ALL), in comparison to paediatric acute myeloid leukaemia (AML).
  • A total of 159 patients entered the study, including 106 ALL (including 86 precursor-B-cell ALL, and 20 T-cell ALL) and 53 AML children.
  • With respect to immunophenotype, ex vivo drug resistance in T-cell ALL (T-ALL) was higher for most of the drugs.
  • No differences in drug resistance between T-ALL and common/pre-B-cell-ALL were found for daunorubicin, mitoxantrone and 6-thioguanine.
  • Bortezomib was the only compound which was more active in T-ALL than in common/pre-B-ALL paediatric samples.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrazines / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20651360.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


14. Coleman CB, Nealy MS, Tibbetts SA: Immature and transitional B cells are latency reservoirs for a gammaherpesvirus. J Virol; 2010 Dec;84(24):13045-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gammaherpesviruses, including Kaposi's sarcoma-associated herpesvirus (KSHV; also known as human herpesvirus 8 [HHV-8]), Epstein-Barr virus (EBV), and murine gammaherpesvirus 68 (MHV68; also known as gammaherpesvirus 68 [γHV68] or murine herpesvirus 4 [MuHV-4]), establish lifelong latency in the resting memory B cell compartment.
  • However, little is known about how this reservoir of infected mature B cells is maintained for the life of the host.
  • In the context of a normal immune system, the mature B cell pool is naturally maintained by the renewable populations of developing B cells that arise from hematopoiesis.
  • Thus, recurrent infection of these developing B cell populations could allow the virus continual access to the B cell lineage and, subsequent to differentiation, the memory B cell compartment.
  • In work described here, we demonstrate the presence of viral genome in bone marrow pro-pre-B cells and immature B cells during early latency and immature B cells during long-term latency.
  • Because developing B cells normally exhibit a short life span and a high rate of turnover, these findings suggest a model in which gammaherpesviruses may gain access to the mature B cell compartment by recurrent seeding of developing B cells.

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Feb;74(3):1101-13 [10627520.001]
  • [Cites] J Virol. 2010 Aug;84(15):7523-34 [20484501.001]
  • [Cites] J Immunol. 2001 Dec 15;167(12):6834-40 [11739500.001]
  • [Cites] Nat Rev Immunol. 2001 Oct;1(1):75-82 [11905817.001]
  • [Cites] J Virol. 2002 Jul;76(14):7125-32 [12072512.001]
  • [Cites] J Virol. 2003 Feb;77(4):2522-9 [12551990.001]
  • [Cites] J Immunol. 2003 Apr 1;170(7):3828-34 [12646650.001]
  • [Cites] J Virol. 2003 Jul;77(13):7308-18 [12805429.001]
  • [Cites] J Virol. 2003 Jul;77(13):7696-701 [12805472.001]
  • [Cites] Cancer. 1979 Sep;44(3):993-1002 [225008.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 1):4262-79 [7030473.001]
  • [Cites] Hum Pathol. 1984 Mar;15(3):290-3 [6321323.001]
  • [Cites] Transplantation. 1985 May;39(5):461-72 [2986325.001]
  • [Cites] Blood. 1985 May;65(5):1097-104 [2986741.001]
  • [Cites] Blood. 1988 May;71(5):1234-43 [2833957.001]
  • [Cites] Blood. 1988 Aug;72(2):520-9 [2840986.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1988 Fall;10(3):196-205 [2845831.001]
  • [Cites] J Gen Virol. 1989 May;70 ( Pt 5):1203-15 [2543775.001]
  • [Cites] J Gen Virol. 1992 Sep;73 ( Pt 9):2347-56 [1328491.001]
  • [Cites] J Immunol. 1993 Nov 1;151(9):4431-44 [8409411.001]
  • [Cites] Blood. 1993 Dec 1;82(11):3259-64 [8241498.001]
  • [Cites] Br J Haematol. 1995 Apr;89(4):704-11 [7772506.001]
  • [Cites] AIDS Res Hum Retroviruses. 1996 May 20;12(8):651-7 [8744575.001]
  • [Cites] J Virol. 1996 Oct;70(10):6775-80 [8794315.001]
  • [Cites] Immunity. 1996 Dec;5(6):527-35 [8986713.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):863-71 [9064346.001]
  • [Cites] Acta Haematol. 1997;98(1):32-6 [9210911.001]
  • [Cites] Science. 1998 Jan 2;279(5347):84-8 [9417030.001]
  • [Cites] Blood. 1998 Mar 15;91(6):1833-44 [9490664.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1074-7 [9781644.001]
  • [Cites] J Virol. 1999 Jun;73(6):4651-61 [10233924.001]
  • [Cites] J Exp Med. 1999 Jul 5;190(1):75-89 [10429672.001]
  • [Cites] J Invest Dermatol. 1999 Oct;113(4):613-6 [10504449.001]
  • [Cites] J Virol Methods. 2005 Jun;126(1-2):91-100 [15847924.001]
  • [Cites] Mod Pathol. 2006 May;19(5):726-37 [16528368.001]
  • [Cites] Blood. 2006 Jul 1;108(1):141-51 [16543476.001]
  • [Cites] Curr Opin Immunol. 2008 Apr;20(2):149-57 [18434123.001]
  • [Cites] J Virol. 2008 Sep;82(17):8500-8 [18562537.001]
  • [Cites] J Virol. 2009 Jul;83(13):6484-93 [19386718.001]
  • [Cites] PLoS One. 2009;4(8):e6492 [19652715.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1378-85 [11070102.001]
  • (PMID = 20926565.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR018724; United States / NCI NIH HHS / CA / R01 CA139984; United States / NCI NIH HHS / CA / CA139984; United States / NCRR NIH HHS / RR / P20-RR018724
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Nuclear Proteins; 0 / latency-associated nuclear antigen
  • [Other-IDs] NLM/ PMC3004345
  •  go-up   go-down


15. Zeller B, Gustafsson G, Forestier E, Abrahamsson J, Clausen N, Heldrup J, Hovi L, Jonmundsson G, Lie SO, Glomstein A, Hasle H, Nordic Society of Paediatric Haematology and Oncology (NOPHO): Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol; 2005 Mar;128(6):797-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukaemia in children with Down syndrome: a population-based Nordic study.
  • To determine the epidemiology and outcome of children with Down syndrome (DS) diagnosed with acute leukaemia in the Nordic countries, data registered in the Nordic Society of Paediatric Haematology and Oncology (NOPHO) population-based leukaemia registry were analysed.
  • Of 3494 children with acute leukaemia diagnosed between July 1984 and December 2001, 136 patients (3.9%) with DS were identified.
  • 2.1% of the children with acute lymphoid leukaemia (ALL) and 14.0% of the children with acute myeloid leukaemia (AML) had DS.
  • None of the DS patients had T cell leukaemia.
  • DS patients with AML had significantly lower platelet and white blood cell counts and two-thirds were type M7 as according to the French-American-British classification.
  • [MeSH-major] Down Syndrome / complications. Leukemia, Myeloid / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Acute Disease. Age Distribution. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Infant, Newborn. Male. Norway / epidemiology

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755283.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


16. Toubai T, Tanaka J, Ota S, Fukuhara T, Hashino S, Kondo T, Kasai M, Kakinoki Y, Masauzi N, Morioka M, Kawamura T, Iwasaki H, Asaka M, Imamura M: Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients. Am J Hematol; 2005 Nov;80(3):181-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients.
  • The median WBC count was 11.3 x 10(9)/L at diagnosis.
  • All patients had L2 type ALL.
  • [MeSH-major] Gene Rearrangement. Gene Rearrangement, T-Lymphocyte. Immunoglobulin Heavy Chains / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Clone Cells. Female. Follow-Up Studies. Gene Rearrangement, delta-Chain T-Cell Antigen Receptor. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Male. Middle Aged. Molecular Diagnostic Techniques. Neoplasm, Residual / diagnosis. Remission Induction. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247752.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


17. Lal R, Prasad DK, Krishna P, Sikora SS, Poddar U, Yachha SK, Kumari N: Biliary atresia with a "cyst at porta": management and outcome as per the cholangiographic anatomy. Pediatr Surg Int; 2007 Aug;23(8):773-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cholangiographic anatomy was classified as; Group A (n = 7), type III BA with extrahepatic cyst; Group B (n = 2), type I or II BA with extrahepatic biliary cyst; and Group C (n = 4), type I or II BA with both extrahepatic and intrahepatic biliary cysts.
  • The remaining 45 patients were comprised of type III BA without a cyst.
  • All 45 patients with type III BA without a cyst were treated by a Kasai's PE.
  • There were three early post-operative deaths, all in patients with type III BA without cyst.
  • Of the remaining 42 patients with type III BA without a cyst, 27 (64.3%) had bile flow, 13 (31%) became jaundice free and 14 (33.3%) have had 1-2 episodes of post-operative cholangitis.
  • The outcome was most satisfactory in type I BA without intrahepatic cystic dilatation (Group B) in terms of achieving a jaundice free state and freedom from recurrent cholangitis.
  • The outcome in type III BA with extrahepatic cyst was comparable to type III BA without cyst.

  • Genetic Alliance. consumer health - Biliary Atresia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 1991 Jan;26(1):32-6 [2005521.001]
  • [Cites] J Pediatr Surg. 1994 May;29(5):630-4 [8035271.001]
  • [Cites] J Formos Med Assoc. 1996 Jul;95(7):567-71 [8840762.001]
  • [Cites] J Pediatr Surg. 1990 Oct;25(10):1076-80; discussion 1081 [2262862.001]
  • [Cites] J Pediatr Surg. 2003 Jul;38(7):997-1000 [12861525.001]
  • [Cites] Radiology. 1998 Nov;209(2):465-9 [9807575.001]
  • [Cites] Pediatr Surg Int. 2006 Oct;22(10):803-7 [16947025.001]
  • [Cites] Eur J Pediatr Surg. 1999 Oct;9(5):340-2 [10584198.001]
  • [Cites] Surgery. 1975 Mar;77(3):384-90 [1124494.001]
  • [Cites] Hepatology. 1996 Aug;24(2):289-93 [8690394.001]
  • [Cites] J Pediatr Surg. 2006 Dec;41(12 ):1973-5 [17161184.001]
  • [Cites] AJR Am J Roentgenol. 1994 Jan;162(1):167-71 [8273658.001]
  • [Cites] J Pediatr Surg. 2000 Dec;35(12 ):1771-4 [11101734.001]
  • [Cites] J Pediatr Surg. 1998 May;33(5):700-4 [9607471.001]
  • [Cites] Eur J Pediatr Surg. 1998 Jun;8(3):146-9 [9676396.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2003 May;36(5):608-12 [12717083.001]
  • [Cites] Surgery. 1974 Feb;75(2):228-32 [4840842.001]
  • [Cites] J Pediatr Surg. 1987 Jun;22(6):522-5 [3612442.001]
  • [Cites] Semin Pediatr Surg. 2005 Feb;14(1):42-8 [15770587.001]
  • (PMID = 17569062.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Higuchi Y, Ito T, Matsuda K, Higuchi T, Hidaka E, Imagawa E, Uhara M, Nakazawa H, Ishida F, Yamauchi K, Sano K, Katsuyama T: [Additional chromosomal changes in impaired chimeric analysis of a patient with relapsed leukemia after bone marrow transplantation]. Rinsho Ketsueki; 2008 Feb;49(2):109-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Additional chromosomal changes in impaired chimeric analysis of a patient with relapsed leukemia after bone marrow transplantation].
  • Chimerism analysis by polymerase chain reaction amplification of short tandem repeats (PCR-STR) has become a routine diagnostic procedure for evaluating grafts and assessing the likeliness of original disease recurrence after allogeneic stem cell transplantation.
  • Following a sex-mismatched hematopoietic stem cell transplantation (HSCT), we monitored the clinical course of a 61-year old male AML M6 patient with trisomy 8 using PCR-STR with a TH01 locus on 11p15 and fluorescence in situ hybridization (FISH) analysis specific for alpha satellite DNA on chromosome 8.
  • Ten months after HSCT, FISH analysis showed 24.8% recipient cells, but PCR-STR demonstrated 100% donor type chimerism.
  • Further XY FISH analysis of May-Grünwald-Giemsa-stained bone marrow samples clearly demonstrated relapse of the original disease and G-banding analysis of bone marrow samples at relapse showed that an additional chromosomal abnormality, del(11) (p10), had deleted the PCR-STR detection site in all recipient type cells.
  • [MeSH-major] Chimerism. Chromosomes, Human, Pair 8 / genetics. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341042.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Larson Gedman A, Chen Q, Kugel Desmoulin S, Ge Y, LaFiura K, Haska CL, Cherian C, Devidas M, Linda SB, Taub JW, Matherly LH: The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia; 2009 Aug;23(8):1417-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
  • We explored the impact of mutations in the NOTCH1, FBW7 and PTEN genes on prognosis and downstream signaling in a well-defined cohort of 47 patients with pediatric T-cell acute lymphoblastic leukemia (T-ALL).
  • NOTCH1 mutations resulted in 1.3- to 3.3-fold increased transactivation of an HES1 reporter construct over wild-type NOTCH1; mutant FBW7 resulted in further augmentation of reporter gene activity.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5925-34 [11486031.001]
  • [Cites] Blood. 2007 Jul 1;110(1):278-86 [17363738.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1203-10 [17873882.001]
  • [Cites] Leukemia. 2008 Jan;22(1):124-31 [17928886.001]
  • [Cites] J Clin Invest. 2008 Nov;118(11):3762-74 [18830414.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3918-24 [19109228.001]
  • [Cites] J Biol Chem. 2001 Sep 21;276(38):35847-53 [11461910.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45031-40 [11564735.001]
  • [Cites] Genes Dev. 2002 Feb 1;16(3):295-300 [11825871.001]
  • [Cites] Immunity. 2002 Feb;16(2):231-43 [11869684.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):673-84 [12209127.001]
  • [Cites] EMBO Rep. 2002 Sep;3(9):840-5 [12223465.001]
  • [Cites] J Cell Physiol. 2003 Mar;194(3):237-55 [12548545.001]
  • [Cites] J Immunol. 2003 Jun 15;170(12):5834-41 [12794108.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):23196-203 [12682059.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6854-7 [15466172.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9265-73 [15485896.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Cell. 1991 Nov 15;67(4):687-99 [1657403.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4243-51 [9373234.001]
  • [Cites] Blood. 1998 Feb 1;91(3):735-46 [9446631.001]
  • [Cites] J Immunol. 1999 Jan 15;162(2):635-8 [9916679.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Cell. 2005 Aug 12;122(3):435-47 [16096062.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8530-7 [16166334.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1074-9 [16489059.001]
  • [Cites] Leukemia. 2006 Mar;20(3):537-9 [16424867.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3043-9 [16707600.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4642-51 [16738328.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] Nat Med. 2007 Jan;13(1):70-7 [17173050.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):451-7 [17255265.001]
  • [Cites] Cell Cycle. 2007 Jan 1;6(1):80-4 [17245125.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5611-6 [17575125.001]
  • [Cites] Development. 2000 Jul;127(14):3185-95 [10862754.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):197-206 [10882062.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):207-16 [10882063.001]
  • [Cites] Immunity. 2000 Jul;13(1):73-84 [10933396.001]
  • [Cites] EMBO J. 2001 Jul 2;20(13):3427-36 [11432830.001]
  • (PMID = 19340001.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA076641-10; United States / NCI NIH HHS / CA / T32-CA009531; United States / NCI NIH HHS / CA / R01 CA076641; United States / NCI NIH HHS / CA / CA76641; United States / NCI NIH HHS / CA / T32 CA009531-22; United States / NCI NIH HHS / CA / T32 CA009531; United States / NCI NIH HHS / CA / T32 CA009531-21
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Cell Cycle Proteins; 0 / DNA, Neoplasm; 0 / F-Box Proteins; 0 / Homeodomain Proteins; 0 / NOTCH1 protein, human; 0 / Neoplasm Proteins; 0 / Receptor, Notch1; 149348-15-2 / HES1 protein, human; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ NIHMS98506; NLM/ PMC2726275
  •  go-up   go-down


20. Eapen M, Rubinstein P, Zhang MJ, Camitta BM, Stevens C, Cairo MS, Davies SM, Doyle JJ, Kurtzberg J, Pulsipher MA, Ortega JJ, Scaradavou A, Horowitz MM, Wagner JE: Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol; 2006 Jan 1;24(1):145-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months.
  • PURPOSE: To describe outcomes after unrelated donor stem cell transplantation (HCT) in children (< 18 months at diagnosis) with acute leukemia and compare these with outcomes after human leukocyte antigen (HLA)-matched sibling donor HCT.
  • PATIENTS AND METHODS: We compared the results of unrelated donor HCT with bone marrow (n = 85) or cord blood grafts (n = 81) and HLA-matched sibling donor HCT with bone marrow grafts (n = 101) for acute myeloid or acute lymphoblastic leukemia using Cox proportional hazards models.
  • Unrelated donor HCT recipients were younger, more likely to have MLL gene rearrangement, to have advanced leukemia, and to receive irradiation before HCT.
  • Risks of relapse, overall and leukemia-free survival were significantly associated with disease status at transplantation.
  • Though leukemia recurrence was lowest after unrelated donor HCT in first clinical remission (CR), overall survival, and leukemia-free survival rates were similar after matched sibling and unrelated donor HCT, after adjustment for disease status.
  • Relapse, overall and leukemia-free survival did not differ by graft type (bone marrow v cord blood) or type of leukemia.
  • Three-year probabilities of leukemia-free survival were 49% and 54% after HLA-matched sibling and unrelated donor transplantation in first CR, respectively.
  • Corresponding rates for those with advanced leukemia were 20% and 30%.
  • CONCLUSION: Unrelated donor HCT should be considered for infants with acute leukemia in first CR using the same eligibility criteria as are currently used for those with HLA matched sibling donors.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Histocompatibility Testing. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16382124.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Tenover FC, Novak-Weekley S, Woods CW, Peterson LR, Davis T, Schreckenberger P, Fang FC, Dascal A, Gerding DN, Nomura JH, Goering RV, Akerlund T, Weissfeld AS, Baron EJ, Wong E, Marlowe EM, Whitmore J, Persing DH: Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol; 2010 Oct;48(10):3719-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches.
  • A total of 2,296 unformed stool specimens, collected from seven study sites, were tested by Xpert C. difficile enrichment culture followed by cell culture cytotoxicity testing of the isolates (i.e., toxigenic culture with enrichment) and the study sites' standard C. difficile test methods.
  • All C. difficile strains were typed by PCR-ribotyping.
  • The Xpert C. difficile assay is a simple, rapid, and accurate method for detection of toxigenic C. difficile in unformed stool specimens and is minimally affected by strain type compared to EIA and GDH-based methods.
  • [MeSH-major] Bacteriological Techniques / methods. Clostridium Infections / diagnosis. Clostridium difficile / isolation & purification. Molecular Diagnostic Techniques / methods

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Nov 25;341(22):1645-51 [10572152.001]
  • [Cites] J Hosp Infect. 2009 Jun;72(2):111-8 [19386381.001]
  • [Cites] J Clin Microbiol. 2003 Sep;41(9):4031-7 [12958221.001]
  • [Cites] J Clin Microbiol. 1986 Mar;23(3):622-3 [3082928.001]
  • [Cites] J Clin Microbiol. 1991 Nov;29(11):2639-42 [1774279.001]
  • [Cites] J Clin Microbiol. 1993 Mar;31(3):507-11 [8458943.001]
  • [Cites] J Clin Microbiol. 1999 Feb;37(2):461-3 [9889244.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2433-41 [16322603.001]
  • [Cites] J Clin Microbiol. 2006 Mar;44(3):1145-9 [16517916.001]
  • [Cites] Clin Microbiol Infect. 2006 Oct;12 Suppl 6:2-18 [16965399.001]
  • [Cites] Clin Infect Dis. 2007 Nov 1;45(9):1152-60 [17918076.001]
  • [Cites] Clin Microbiol Infect. 2007 Nov;13(11):1048-57 [17850341.001]
  • [Cites] Clin Infect Dis. 2007 Nov 15;45(10):1266-73 [17968819.001]
  • [Cites] J Clin Microbiol. 2007 Nov;45(11):3601-5 [17804652.001]
  • [Cites] Euro Surveill. 2007 Jun;12(6):E1-2 [17991399.001]
  • [Cites] Infect Control Hosp Epidemiol. 2008 Mar;29(3):197-202 [18241032.001]
  • [Cites] J Clin Microbiol. 2008 Apr;46(4):1523-5 [18256226.001]
  • [Cites] J Clin Microbiol. 2008 Jun;46(6):1996-2001 [18434563.001]
  • [Cites] N Engl J Med. 2008 Oct 30;359(18):1932-40 [18971494.001]
  • [Cites] J Clin Microbiol. 2008 Nov;46(11):3833-5 [18784313.001]
  • [Cites] J Clin Microbiol. 2008 Nov;46(11):3686-9 [18845820.001]
  • [Cites] J Clin Microbiol. 2009 Feb;47(2):373-8 [19073875.001]
  • [Cites] Ann Intern Med. 2009 Aug 4;151(3):176-9 [19652187.001]
  • [Cites] J Clin Microbiol. 2009 Sep;47(9):3004-7 [19571021.001]
  • [Cites] J Clin Microbiol. 2009 Oct;47(10):3211-7 [19710274.001]
  • [Cites] J Clin Microbiol. 2009 Nov;47(11):3729-31 [19741082.001]
  • [Cites] Anaerobe. 2009 Dec;15(6):270-3 [19853666.001]
  • [Cites] J Clin Microbiol. 2009 Dec;47(12):3846-50 [19846637.001]
  • [Cites] J Clin Microbiol. 2010 Jan;48(1):124-30 [19923482.001]
  • [Cites] Diagn Microbiol Infect Dis. 2010 Feb;66(2):129-34 [20117349.001]
  • [Cites] J Clin Microbiol. 2010 Feb;48(2):603-5 [19955275.001]
  • [Cites] J Clin Microbiol. 2010 Feb;48(2):606-8 [20032256.001]
  • [Cites] J Clin Microbiol. 2010 Mar;48(3):889-93 [20071552.001]
  • [Cites] Infect Control Hosp Epidemiol. 2009 Mar;30(3):264-72 [19215193.001]
  • [Cites] Nature. 2009 Apr 30;458(7242):1176-9 [19252482.001]
  • [Cites] Infect Control Hosp Epidemiol. 2002 Nov;23(11):639-40 [12452289.001]
  • (PMID = 20702676.001).
  • [ISSN] 1098-660X
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2953097
  •  go-up   go-down


22. Hildebrandt P, Richards AM: Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension. Am J Cardiol; 2008 Feb 4;101(3A):21-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension.
  • Although the current value of amino-terminal pro-B-type natriuretic peptides (NT-proBNP) to generally screen populations of "apparently well patients" remains promising but still undefined, the use of NT-proBNP to screen patients at high risk for heart disease (such as elderly patients, or patients with diabetes mellitus, hypertension, or known coronary artery disease) appears logical and is supported by data.

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18243853.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  • [Number-of-references] 19
  •  go-up   go-down


23. Ma X, Buffler PA, Wiemels JL, Selvin S, Metayer C, Loh M, Does MB, Wiencke JK: Ethnic difference in daycare attendance, early infections, and risk of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev; 2005 Aug;14(8):1928-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethnic difference in daycare attendance, early infections, and risk of childhood acute lymphoblastic leukemia.
  • A role for infectious agents has been proposed in the etiology of childhood acute lymphoblastic leukemia (ALL), particularly for common ALL (c-ALL; ALL diagnosed in children ages 2-5 years and expressing CD10 and CD19 surface antigens).
  • We evaluated the possible etiologic role of daycare attendance (a proxy measure for exposure to infectious agents) and infections during infancy in the Northern California Childhood Leukemia Study.
  • The magnitude of effect associated with the same number of child-hours was stronger for daycare attendance during infancy than for daycare attendance before diagnosis.
  • [MeSH-major] Child Day Care Centers. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Child Care.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103439.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCHHSTP CDC HHS / PS / PS42 ES04705; United States / NIEHS NIH HHS / ES / R01 ES09137
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


24. Liao C, Liu B, Huang YN, Xu ZP, Gu SL, Wu SQ, Chen JS, Li Y, Tang XW, Xie XM: [Retrospective analysis of 54 cases of unrelated umbilical cord blood transplantation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Apr;13(2):240-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The time of nuclear cell reconstitution after cord blood transplantation was statistically related with nucleated cells and the type of disease, not related with HLA matching.
  • Acute GVHD was present in 8 patients (21.6%) and chronic GVHD occurred in 2 patients (5.4%), 6 patients suffered from graft failure (11.1%).

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854284.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


25. Zhang Y, Wang Y, Huang L, Chen D, Tao Y, Yuan Z: Effects of cooking and storage on residues of cyadox in chicken muscle. J Agric Food Chem; 2005 Dec 14;53(25):9737-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The heat stabilities of cyadox (CYX) and its two metabolites, 1,4-bisdesoxycyadox (BDCYX) and quinoxaline-2-carboxylic acid (QCA), in water, cooking oil, and as incurred residues in chicken muscle were investigated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16332123.001).
  • [ISSN] 0021-8561
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinoxalines; 65884-46-0 / cyadox
  •  go-up   go-down


26. Terme JM, Mocquet V, Kuhlmann AS, Zane L, Mortreux F, Wattel E, Duc Dodon M, Jalinot P: Inhibition of the hTERT promoter by the proto-oncogenic protein TAL1. Leukemia; 2009 Nov;23(11):2081-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report, we show that the basic helix-loop-helix factor, TAL1 (T-cell acute lymphoblastic leukemia 1), is a negative regulator of the hTERT promoter.
  • Considering the relationship recently established between TAL1 and the human T-cell leukemia virus type 1 (HTLV-1) Tax protein, which was confirmed in T lymphocyte clones derived from adult T-cell leukemia patients, we analyzed the effect of TAL1 with respect to the earlier characterized effects of Tax and HBZ (HTLV-1 basic leucine zipper) on hTERT expression.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / metabolism. Gene Expression Regulation, Leukemic / physiology. Leukemia, T-Cell / genetics. Proto-Oncogene Proteins / metabolism. Telomerase / genetics. Telomerase / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19587703.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Basic-Leucine Zipper Transcription Factors; 0 / Gene Products, tax; 0 / HBZ protein, human T-cell leukemia virus type I; 0 / Proto-Oncogene Proteins; 0 / Sp1 Transcription Factor; 0 / Viral Proteins; 0 / tax protein, Human T-lymphotrophic virus 1; 135471-20-4 / TAL1 protein, human; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


27. Zhu HY, DA WM, Gao CJ, Han XP, Wang SH, Jing Y, Bo J, Jin HJ, Li M: [Allogeneic peripheral blood hematopoietic stem cell transplantation for post-operatively treating acute non-lymphocytic leukemia patient complicated with renal cell carcinoma: one case report]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb;16(1):203-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Allogeneic peripheral blood hematopoietic stem cell transplantation for post-operatively treating acute non-lymphocytic leukemia patient complicated with renal cell carcinoma: one case report].
  • The aim of this study was to evaluate the safety and efficacy of allogeneic hematopoietic peripheral blood stem cell transplantation (allo-PBHSCT) for post-operative therapy of acute non-lymphocytic leukemia (ANLL) patient complicated with renal cell carcinoma (RCC).
  • The results indicated that the patient achieved engraftment 16 days after transplantation with full donor-type chimerism detected by STR-PCR at 30 and 100 days after transplantation.
  • No acute or chronic GVHD and any severe complication developed.


28. Airoldi I, Cocco C, Di Carlo E, Disarò S, Ognio E, Basso G, Pistoia V: Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells. Cancer Res; 2006 Apr 15;66(8):3978-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells.
  • The aim of this study was to investigate (i) whether the IL-12Rbeta2 gene is silenced in B-cell acute lymphoblastic leukemia (B-ALL) cells, and (ii) what the functional implications of such silencing for tumor growth are.
  • Here, we show that although mature B cells expressed both chains of the IL-12R, normal pro-B and pre-B cells failed to express the IL-12Rbeta2 chain.
  • Similarly, primary tumor cells from pediatric pro-B, early pre-B, and pre-B ALL (30 cases) did not express the IL-12Rbeta2 chain.
  • Such methylation was not detected in normal early B cells that when differentiated into mature B cells expressed the IL-12Rbeta2 gene.
  • Detection of IL-12Rbeta2 mRNA and protein in the tumorigenic 697 pre-B-ALL cell line allowed to perform functional experiments in severe combined immunodeficient/nonobese diabetic mice receiving 697 cells with or without human recombinant IL-12 (hrIL-12).
  • [MeSH-major] Burkitt Lymphoma / genetics. DNA Methylation. Receptors, Interleukin / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618714.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / IL12RB2 protein, human; 0 / Il12rb2 protein, mouse; 0 / Receptors, Interleukin; 0 / Receptors, Interleukin-12
  •  go-up   go-down


29. van Zelm MC, van der Burg M, de Ridder D, Barendregt BH, de Haas EF, Reinders MJ, Lankester AC, Révész T, Staal FJ, van Dongen JJ: Ig gene rearrangement steps are initiated in early human precursor B cell subsets and correlate with specific transcription factor expression. J Immunol; 2005 Nov 1;175(9):5912-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ig gene rearrangement steps are initiated in early human precursor B cell subsets and correlate with specific transcription factor expression.
  • The role of specific transcription factors in the initiation and regulation of Ig gene rearrangements has been studied extensively in mouse models, but data on normal human precursor B cell differentiation are limited.
  • We purified five human precursor B cell subsets, and assessed and quantified their IGH, IGK, and IGL gene rearrangement patterns and gene expression profiles.
  • Pro-B cells already massively initiate D(H)-J(H) rearrangements, which are completed with V(H)-DJ(H) rearrangements in pre-B-I cells.
  • Large cycling pre-B-II cells are selected for in-frame IGH gene rearrangements.
  • The first IGK/IGL gene rearrangements were initiated in pre-B-I cells, but their frequency increased enormously in small pre-B-II cells, and in-frame selection was found in immature B cells.
  • Transcripts of the RAG1 and RAG2 genes and earlier defined transcription factors, such as E2A, early B cell factor, E2-2, PAX5, and IRF4, were specifically up-regulated at stages undergoing Ig gene rearrangements.
  • Based on the combined Ig gene rearrangement status and gene expression profiles of consecutive precursor B cell subsets, we identified 16 candidate genes involved in initiation and/or regulation of Ig gene rearrangements.
  • These analyses provide new insights into early human precursor B cell differentiation steps and represent an excellent template for studies on oncogenic transformation in precursor B acute lymphoblastic leukemia and B cell differentiation blocks in primary Ab deficiencies.
  • [MeSH-minor] Adolescent. Cell Separation. Child. Child, Preschool. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Gene Rearrangement, B-Lymphocyte, Light Chain. Humans

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Immunol. 2006 Jun 15;176(12):7787
  • (PMID = 16237084.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transcription Factors
  •  go-up   go-down


30. Ran YC, Ao XX, Liu L, Fu YL, Tuo H, Xu F: [Distribution and drug resistance of pathogenic bacteria isolated from infected wounds of children after Wenchuan earthquake]. Zhonghua Er Ke Za Zhi; 2009 May;47(5):332-6; discussion 336-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acinetobacter baumanii was the most common organism isolated from wounds.
  • Drug sensitivity tests displayed that the isolated bacteria were highly resistant to common antibiotics.
  • One strain of Acinetobacter baumanii-calcoaceticus complex and six strains of Acinetobacter baumanii were resistant to all common antibiotics including imipenem/cilastatin.
  • CONCLUSION: Following the Wenchuan earthquake disaster, wound infection profiles of pediatric patients were significantly different, Acinetobacter baumanii was the main common organism isolated from wounds in contrast to the previous low isolation rate.


31. Bhardwaj A, Rehman SU, Mohammed A, Baggish AL, Moore SA, Januzzi JL Jr: Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. Am Heart J; 2010 Apr;159(4):532-538.e1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
  • BACKGROUND: Serial measurements of N-terminal pro-B type natriuretic peptide (NT-proBNP) provide prognostic information in patients with chronic heart failure (HF).
  • CONCLUSIONS: The Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study will test the hypothesis that therapy guided by NT-proBNP concentrations will be superior to standard of care HF management (www.clinicaltrials.gov identifier NCT00351390).

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20362709.001).
  • [ISSN] 1097-6744
  • [Journal-full-title] American heart journal
  • [ISO-abbreviation] Am. Heart J.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00351390
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


32. Hayslip J, Montero A: Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review. Mol Cancer; 2006;5:44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transcriptional silencing of tumor suppressor genes, associated with DNA methylation, is a common epigenetic event in hematologic malignancies.
  • Although DNA hypermethylation of CpG islands is well described in acute leukemias and myelodysplastic syndromes, much less is known of the specific methylation changes that commonly occur in follicular B cell lymphomas.
  • Earlier methylation studies of follicular lymphoma involved only cell lines; however there is a growing literature of methylation changes in primary human FL samples.
  • Methylation of cyclin dependent kinase inhibitors is more common in high grade lymphomas, and may be an important step in the progression and transformation of follicular lymphoma.
  • [MeSH-minor] Animals. Annexin A1 / genetics. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Apoptosis Regulatory Proteins / genetics. Calcium-Calmodulin-Dependent Protein Kinases / genetics. Cell Transformation, Neoplastic / genetics. Cyclin-Dependent Kinases / genetics. Death-Associated Protein Kinases. Epigenesis, Genetic. Glutathione S-Transferase pi / genetics. Humans. Interleukin-12 Receptor beta 2 Subunit / genetics. Intracellular Signaling Peptides and Proteins / genetics. Protein Tyrosine Phosphatase, Non-Receptor Type 6 / genetics. Protein-Serine-Threonine Kinases / genetics. Receptors, Androgen / genetics

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5019-26 [15983392.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6442-9 [16166418.001]
  • [Cites] Ann Hematol. 2005 Dec;84 Suppl 1:18-24 [16273408.001]
  • [Cites] Blood. 2006 Jan 1;107(1):250-6 [16160013.001]
  • [Cites] J Immunol. 2006 Apr 1;176(7):4083-93 [16547244.001]
  • [Cites] Genet Res. 2006 Jun;87(3):187-93 [16818001.001]
  • [Cites] Pharmacol Ther. 1999 Dec;84(3):389-400 [10665836.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jul;28(3):246-57 [10862030.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51 [10922409.001]
  • [Cites] Pharmacology. 2000 Sep;61(3):154-66 [10971201.001]
  • [Cites] J Immunol. 2000 Dec 15;165(12):6880-8 [11120812.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Jan;296(1):1-6 [11123355.001]
  • [Cites] Ann Intern Med. 2001 Apr 3;134(7):573-86 [11281740.001]
  • [Cites] Int Immunol. 2001 Apr;13(4):553-8 [11282994.001]
  • [Cites] Br J Pharmacol. 2001 May;133(2):217-28 [11350857.001]
  • [Cites] Hum Mol Genet. 2001 Jun 1;10(12):1265-73 [11406608.001]
  • [Cites] Haematologica. 2002 Apr;87(4):434-42 [11940489.001]
  • [Cites] Endocr Rev. 2002 Apr;23(2):175-200 [11943742.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2429-40 [12011120.001]
  • [Cites] J Cell Physiol. 2002 Sep;192(3):327-38 [12124778.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2572-7 [12239171.001]
  • [Cites] Nat Rev Immunol. 2003 Feb;3(2):133-46 [12563297.001]
  • [Cites] Cancer Sci. 2003 Jan;94(1):87-91 [12708480.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(16):5556-71 [12897130.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(19):6936-43 [12972611.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4034-42 [14519624.001]
  • [Cites] Clin Immunol. 2003 Oct;109(1):89-102 [14585280.001]
  • [Cites] Lab Invest. 2003 Dec;83(12):1849-58 [14691303.001]
  • [Cites] Leukemia. 2004 Feb;18(2):356-8 [14614518.001]
  • [Cites] Haematologica. 2004 Feb;89(2):154-64 [15003890.001]
  • [Cites] BMC Cancer. 2004 Mar 8;4:8 [15070421.001]
  • [Cites] J Clin Invest. 2004 Jun;113(11):1651-9 [15173892.001]
  • [Cites] J Exp Med. 1972 Nov 1;136(5):1098-116 [4538840.001]
  • [Cites] Cancer Treat Rep. 1977 Jan-Feb;61(1):51-4 [67893.001]
  • [Cites] Cancer Treat Rep. 1977 Jan-Feb;61(1):55-8 [67894.001]
  • [Cites] Cancer Res. 1985 Jul;45(7):3359-63 [2408749.001]
  • [Cites] Nature. 1985 Nov 28-Dec 4;318(6044):377-80 [2999610.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4776-81 [3524819.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):89-93 [1670995.001]
  • [Cites] Science. 1991 Apr 5;252(5002):117-20 [1901424.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):704-7 [8259215.001]
  • [Cites] Science. 1994 Apr 15;264(5157):436-40 [8153634.001]
  • [Cites] Nature. 1994 Sep 15;371(6494):257-61 [8078588.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6353-8 [7987828.001]
  • [Cites] Blood. 1994 Dec 15;84(12):4038-44 [7994022.001]
  • [Cites] Genes Dev. 1995 Jan 1;9(1):15-30 [7828849.001]
  • [Cites] Cancer Res. 1995 Feb 1;55(3):514-7 [7834619.001]
  • [Cites] Blood. 1995 Feb 15;85(4):893-901 [7849311.001]
  • [Cites] Genes Dev. 1995 Mar 15;9(6):639-49 [7729683.001]
  • [Cites] J Exp Med. 1995 Jun 1;181(6):2077-84 [7539038.001]
  • [Cites] Immunity. 1995 Jan;2(1):13-24 [7600299.001]
  • [Cites] Blood. 1995 Aug 1;86(3):841-54 [7620180.001]
  • [Cites] Cell. 1995 Dec 15;83(6):993-1000 [8521522.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14002-7 [8943050.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):837-41 [9041182.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2500-6 [9116295.001]
  • [Cites] Oncogene. 1997 Jul 24;15(4):403-7 [9242376.001]
  • [Cites] Cell. 1997 Nov 28;91(5):649-59 [9393858.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2977-84 [9531609.001]
  • [Cites] Leukemia. 1998 Jun;12(6):937-41 [9639423.001]
  • [Cites] Am J Pathol. 1998 Sep;153(3):887-97 [9736037.001]
  • [Cites] Cell. 1998 Nov 13;95(4):521-30 [9827804.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4347-53 [10361133.001]
  • [Cites] J Cell Biol. 1999 Jul 12;146(1):141-8 [10402466.001]
  • [Cites] Biochem Pharmacol. 1999 Aug 15;58(4):539-55 [10413291.001]
  • [Cites] Blood. 1999 Sep 1;94(5):1773-81 [10477703.001]
  • [Cites] Oncologist. 2005 Mar;10(3):176-82 [15793220.001]
  • (PMID = 17026765.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A1; 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / GADD45 protein; 0 / Interleukin-12 Receptor beta 2 Subunit; 0 / Intracellular Signaling Peptides and Proteins; 0 / Receptors, Androgen; 0 / Tumor Suppressor Proteins; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.7.11.- / PLK2 protein, human; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; EC 2.7.11.22 / Cyclin-Dependent Kinases; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 6
  • [Number-of-references] 68
  • [Other-IDs] NLM/ PMC1629025
  •  go-up   go-down


33. Fernandez-Boyanapalli R, McPhillips KA, Frasch SC, Janssen WJ, Dinauer MC, Riches DW, Henson PM, Byrne A, Bratton DL: Impaired phagocytosis of apoptotic cells by macrophages in chronic granulomatous disease is reversed by IFN-γ in a nitric oxide-dependent manner. J Immunol; 2010 Oct 1;185(7):4030-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diverse M populations from CGD (gp91(phox)(-/-)) and wild-type mice, as well as human Ms differentiated from monocytes and promyelocytic leukemia PLB-985 cells (with and without mutation of the gp91(phox)), demonstrated enhanced engulfment of apoptotic cells in response to IFN-γ priming.
  • Importantly, during acute sterile peritonitis, IFN-γ treatment reduced excess accumulation of apoptotic neutrophils and enhanced phagocytosis by CGD Ms. These data support the hypothesis that in addition to correcting immunodeficiency in CGD, IFN-γ priming of Ms restores clearance of apoptotic cells and may thereby contribute to resolution of exaggerated CGD inflammation.

  • Genetic Alliance. consumer health - Chronic Granulomatous Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20805415.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL68864; United States / NIAID NIH HHS / AI / R01 AI058228; United States / NHLBI NIH HHS / HL / R01 HL081151; United States / NHLBI NIH HHS / HL / P01 HL034303; United States / NHLBI NIH HHS / HL / HL34303; United States / NHLBI NIH HHS / HL / R01 HL068864; United States / NIAID NIH HHS / AI / R56 AI058228; United States / NIGMS NIH HHS / GM / R01 GM061031; United States / NIAID NIH HHS / AI / AI058228; United States / NHLBI NIH HHS / HL / HL 81151; United States / NIGMS NIH HHS / GM / GM61031
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 31C4KY9ESH / Nitric Oxide; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS665328; NLM/ PMC4346245
  •  go-up   go-down


34. Liu YQ, Zhang YZ, Sun CY, Gao PJ: A novel approach to estimate in vitro antibacterial potency of Chinese medicine using a concentration-killing curve method. Am J Chin Med; 2005;33(4):671-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel approach to estimate in vitro antibacterial potency of Chinese medicine using a concentration-killing curve method.
  • The antibacterial pharmacodynamics against E. coli of Chinese medicine (CM) Rhizoma coptidis (Coptis Root) and its formula Sanhuang, and the control antibiotics enoxacin, were analyzed by a concentration-killing curve (CKC) approach, and the novel parameters BC50 and r for antibacterial potency were proposed.
  • Using the agar plate method, about 400 cells of E. coli were evenly inoculated into LB agar plates containing a series of different concentrations of CM or antibiotic, and after a 24 hour incubation at 37 degrees C, all the viable colonies were enumerated.
  • This resulted in a sigmoid concentration-killing curve , in which No, that could be closely fitted (R2 > 0.9) with the function: N = 1 + e(r(x-BC50))/N0 in which N0, BC50 and r represent meaningfully inoculums size, median bactericidal concentration, and bactericidal intensity, respectively.
  • N modeled the survival of colony-forming units on each plate (CFU/plate) in a concentration series x of the drug.
  • The CKC was symmetrical about its single inflexion (BC50, N0/2).
  • Therefore theoretically, 2BC50 can replace MBC (minimum bactericidal concentration).
  • BC1 = BC50 + r/ln(N0-1), the drug concentration at r which only one colony survived, was the least critical value of MBC in CKC.
  • The parameters 2BC50 and BC1 agreed more closely with the definition of MBC, and were little affected by either the biochemical basis of the antibacterial or the inoculum's size (200-400 CFU/plate), and were determined by a multi-point curve.
  • As a result, these were more accurate, reproducible and practical as metrics than was the endpoint of MBC.
  • The two-dimensional CKC, involving BC50 and r, captures the intrinsic dynamics of the antibacterial effect of CM/strain versus concentration, and it is consistent with the Logistic equation of the bacterial growth curve in the format.
  • This verified approach has considerable value as a tool for the accurate and proper administration of CM.
  • The CKC of CM, different from that of antibiotics, is likely to be the resultant force of each ingredient in certain CM, which provides a clue to solve the problem of antibiotic resistance.
  • [MeSH-major] Escherichia coli / drug effects. Medicine, Chinese Traditional. Microbial Sensitivity Tests / methods. Models, Biological
  • [MeSH-minor] Coptis. In Vitro Techniques. Plant Bark. Reproducibility of Results. Rheum

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173540.001).
  • [ISSN] 0192-415X
  • [Journal-full-title] The American journal of Chinese medicine
  • [ISO-abbreviation] Am. J. Chin. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


35. Pasqualucci L, Liso A, Martelli MP, Bolli N, Pacini R, Tabarrini A, Carini M, Bigerna B, Pucciarini A, Mannucci R, Nicoletti I, Tiacci E, Meloni G, Specchia G, Cantore N, Di Raimondo F, Pileri S, Mecucci C, Mandelli F, Martelli MF, Falini B: Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. Blood; 2006 Dec 15;108(13):4146-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification.
  • Because of a lack of specific clonality markers, information on lineage involvement and cell of origin of acute myeloid leukemia with normal karyotype (AML-NK), is missing.
  • Aberrant cytoplasmic expression of mutated NPM proteins was identified with anti-NPM antibodies in 2 or more myeloid hemopoietic cell lineages in 99 (61.5%) of 161 of NPMc+ AML paraffin-embedded bone marrow biopsies; lymphoid involvement was excluded in 3 investigated cases.
  • These findings suggest that NPMc+ AML derives from either a common myeloid or earlier progenitor.
  • Immunohistochemical studies show that varying combinations and ratios of NPMc+ leukemic cells from distinct lineages are responsible for heterogeneity within each French-American-British (FAB) classification type and for NPMc+ AML falling into different FAB categories.
  • [MeSH-major] Biomarkers, Tumor / genetics. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / genetics. Mutation. Nuclear Proteins / genetics


36. Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang CL, Garneau K, Solomon DH: Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther; 2010;12(4):R154
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Although osteoporosis has been reported to be more common in patients with rheumatoid arthritis (RA), little is known whether the risk of osteoporotic fractures in these patients differs by age, sex, and anatomic site.
  • The RRs were elevated in RA patients across all common sites of osteoporotic fracture: hip (1.62, 95% CI 1.43 to 1.84), wrist (1.15, 95% CI 1.00 to 1.32), pelvis (2.02, 95% CI 1.77 to 2.30), and humerus (1.51, 95% CI 1.27 to 1.84).

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Fractures.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2006 Dec;54(12):3790-8 [17136752.001]
  • [Cites] Arthritis Rheum. 2006 Oct;54(10):3104-12 [17009229.001]
  • [Cites] Best Pract Res Clin Rheumatol. 2007 Oct;21(5):885-906 [17870034.001]
  • [Cites] J Rheumatol. 2007 Oct;34(10):1971-5 [17896806.001]
  • [Cites] Clin Rheumatol. 2008 May;27(5):565-72 [17909741.001]
  • [Cites] Mod Rheumatol. 2008;18(2):170-6 [18297237.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1952-8 [18285417.001]
  • [Cites] Am Heart J. 2008 Aug;156(2):336-41 [18657665.001]
  • [Cites] Rheumatol Int. 2008 Sep;28(11):1143-50 [18446340.001]
  • [Cites] J Rheumatol. 2008 Sep;35(9):1704-8 [18634160.001]
  • [Cites] Arthritis Res Ther. 2008;10(4):R95 [18717997.001]
  • [Cites] Ann Rheum Dis. 2009 Mar;68(3):373-6 [18408246.001]
  • [Cites] Arthritis Res Ther. 2008;10(6):R128 [18986531.001]
  • [Cites] J Clin Rheumatol. 2009 Jun;15(4):155-60 [19363452.001]
  • [Cites] Menopause. 2009 Sep-Oct;16(5):950-5 [19387415.001]
  • [Cites] Semin Arthritis Rheum. 2009 Oct;39(2):116-22 [18585759.001]
  • [Cites] BMC Public Health. 2009;9:344 [19761614.001]
  • [Cites] JAMA. 2009 Nov 25;302(20):2214-21 [19934422.001]
  • [Cites] Curr Osteoporos Rep. 2009 Dec;7(4):134-9 [19968917.001]
  • [Cites] Osteoporos Int. 2010 Jun;21 Suppl 2:S407-13 [20464374.001]
  • [Cites] Arthritis Rheum. 2000 Mar;43(3):522-30 [10728744.001]
  • [Cites] J Rheumatol. 2000 Nov;27(11):2582-9 [11093437.001]
  • [Cites] Rheum Dis Clin North Am. 2001 May;27(2):283-303 [11396093.001]
  • [Cites] Am J Epidemiol. 2001 Nov 1;154(9):854-64 [11682368.001]
  • [Cites] Ann Rheum Dis. 2003 Apr;62(4):347-9 [12634235.001]
  • [Cites] Arthritis Rheum. 2003 Apr;48(4):917-26 [12687533.001]
  • [Cites] J Clin Epidemiol. 2003 Mar;56(3):221-9 [12725876.001]
  • [Cites] Arthritis Rheum. 2004 Apr;50(4):1066-76 [15077288.001]
  • [Cites] Rheumatology (Oxford). 2004 Oct;43(10):1267-71 [15252210.001]
  • [Cites] Arthritis Rheum. 1984 Dec;27(12):1353-61 [6508860.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] J Rheumatol. 1991 Jun;18(6):804-8 [1895260.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] J Clin Epidemiol. 1992 Jul;45(7):703-14 [1619449.001]
  • [Cites] J Rheumatol. 1993 Oct;20(10):1666-9 [8295176.001]
  • [Cites] Ann Rheum Dis. 1994 Jan;53(1):18-23 [8311549.001]
  • [Cites] Spine (Phila Pa 1976). 1994 Sep 15;19(18):2117-21 [7825055.001]
  • [Cites] N Engl J Med. 1995 Mar 23;332(12):767-73 [7862179.001]
  • [Cites] J Bone Miner Res. 1995 Feb;10(2):257-63 [7754805.001]
  • [Cites] Lancet. 1996 Jul 20;348(9021):145-9 [8684153.001]
  • [Cites] Bone. 1998 Aug;23(2):75-81 [9701464.001]
  • [Cites] Lancet. 1999 Jul 17;354(9174):220-1 [10421309.001]
  • [Cites] J Clin Epidemiol. 2005 Apr;58(4):323-37 [15862718.001]
  • [Cites] Osteoporos Int. 2005 Jun;16(6):581-9 [15616758.001]
  • [Cites] Arch Intern Med. 2005 Jun 13;165(11):1293-7 [15956010.001]
  • [Cites] J Crit Care. 2005 Mar;20(1):12-9 [16015512.001]
  • [Cites] Osteoporos Int. 2005 Oct;16(10):1263-71 [15702263.001]
  • [Cites] J Bone Miner Res. 2007 Jul;22(7):1088-95 [17419681.001]
  • (PMID = 20682035.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR056215; United States / NIAMS NIH HHS / AR / P60 AR047782; United States / NIDCR NIH HHS / DE / R21 DE018750; United States / NIAMS NIH HHS / AR / K24 AR055989; United States / NIAMS NIH HHS / AR / AR055989; United States / NIAMS NIH HHS / AR / T32 AR 055885
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2945054
  •  go-up   go-down


37. Abdelhameed A, Pond GR, Mitsakakis N, Brandwein J, Chun K, Gupta V, Kamel-Reid S, Lipton JH, Minden MD, Schimmer A, Schuh A, Yee K, Messner HA: Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation. Cancer; 2008 Apr 1;112(7):1513-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
  • BACKGROUND: Evaluation of therapeutic outcomes and risk factors was undertaken for patients with primary solid tumors (PST) developing acute leukemia or myelodysplasia (MDS) as a second malignancy.
  • METHODS: In all, 131 consecutive patients presenting to a single institution with leukemia or MDS after treatment for PST with surgery or chemotherapy/radiotherapy were examined.
  • Management of the secondary acute leukemia and MDS consisted either of intensive therapy including allogeneic blood and marrow transplants or supportive measures.
  • RESULTS: The time from diagnosis of PST to development of acute leukemia or MDS, the cytogenetic profile of patients, and their survival were similar irrespective of PST therapy with surgery alone or strategies involving chemotherapy and/or radiation.
  • CONCLUSIONS: Patients developing acute leukemia or MDS after PST demonstrated similar cytogenetic profiles and clinical outcomes independent of the type of treatment.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Myelodysplastic Syndromes / etiology. Neoplasms / therapy. Neoplasms, Second Primary / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology


38. Winkel TA, Schouten O, Hoeks SE, Flu WJ, Hampton D, Kirchhof P, van Kuijk JP, Lindemans J, Verhagen HJ, Bax JJ, Poldermans D: Risk factors and outcome of new-onset cardiac arrhythmias in vascular surgery patients. Am Heart J; 2010 Jun;159(6):1108-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cardiac risk factors, inflammatory status, and left ventricular function (LVF; N-terminal pro-B-type natriuretic peptide and echocardiography) were assessed.
  • CONCLUSION: New-onset perioperative arrhythmias are common after vascular surgery.

  • MedlinePlus Health Information. consumer health - Arrhythmia.
  • MedlinePlus Health Information. consumer health - Vascular Diseases.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20569727.001).
  • [ISSN] 1097-6744
  • [Journal-full-title] American heart journal
  • [ISO-abbreviation] Am. Heart J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Dieplinger B, Haltmayer M, Poelz W, Mueller T: Value of adiponectin as predictor of 5-year all-cause mortality in patients with symptomatic peripheral arterial disease: results from the Linz Peripheral Arterial Disease (LIPAD) study. Clin Chim Acta; 2009 Oct;408(1-2):87-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We have previously demonstrated that adiponectin is associated with amino terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with peripheral artery disease (PAD).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19646980.001).
  • [ISSN] 1873-3492
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Biomarkers
  •  go-up   go-down


40. Deshpande VS, Kehrer JP: Oxidative stress-driven mechanisms of nordihydroguaiaretic acid-induced apoptosis in FL5.12 cells. Toxicol Appl Pharmacol; 2006 Aug 1;214(3):230-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nordihydroguaiaretic acid (NDGA), a general lipoxygenase (LOX) enzyme inhibitor, induces apoptosis independently of its activity as a LOX inhibitor in murine pro-B lymphocytes (FL.12 cells) by a mechanism that is still not fully understood.
  • [MeSH-minor] Acetylcysteine / pharmacology. Animals. Caspase 3. Caspases / metabolism. Cell Line. Cytochromes c / metabolism. Dithiothreitol / pharmacology. Electrophoresis, Polyacrylamide Gel. Enzyme Inhibitors / pharmacology. Mice. Mitogen-Activated Protein Kinases / metabolism. Phosphorylation

  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16473382.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA83701
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Lipoxygenase Inhibitors; 7BO8G1BYQU / Masoprocol; 9007-43-6 / Cytochromes c; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; T8ID5YZU6Y / Dithiothreitol; WYQ7N0BPYC / Acetylcysteine
  •  go-up   go-down


41. Irish JM, Anensen N, Hovland R, Skavland J, Børresen-Dale AL, Bruserud O, Nolan GP, Gjertsen BT: Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood; 2007 Mar 15;109(6):2589-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53.
  • Loss or mutation of the TP53 tumor suppressor gene is not commonly observed in acute myeloid leukemia (AML), suggesting that there is an alternate route for cell transformation.
  • We investigated the hypothesis that previously observed Bcl-2 family member overexpression suppresses wild-type p53 activity in AML.
  • We demonstrate that wild-type p53 protein is expressed in primary leukemic blasts from patients with de novo AML using 2-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and phospho-specific flow cytometry.
  • Bcl-2 inhibition might therefore improve the efficacy of existing AML therapies by inactivating this suppression of wild-type p53 activity.
  • [MeSH-major] Gene Expression. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism. Tyrosine / metabolism. fms-Like Tyrosine Kinase 3 / metabolism


42. Nielsen CH, Balachandran P, Christensen O, Pugh ND, Tamta H, Sufka KJ, Wu X, Walsted A, Schjørring-Thyssen M, Enevold C, Pasco DS: Enhancement of natural killer cell activity in healthy subjects by Immulina®, a Spirulina extract enriched for Braun-type lipoproteins. Planta Med; 2010 Nov;76(16):1802-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancement of natural killer cell activity in healthy subjects by Immulina®, a Spirulina extract enriched for Braun-type lipoproteins.
  • We further characterized Immulina® by determining that Braun-type lipoproteins are responsible for a major portion of the IN VITRO monocyte activation exhibited by this material.
  • In order to understand the effect of Immulina® on NK cell activity, a pilot study was conducted on ten healthy North American individuals who supplemented their diet with Immulina® (400 mg/day) for seven days.
  • In a separate placebo-controlled, crossover study involving 11 healthy Danish subjects, we observed increased mRNA expression of the NK cell marker NKG2D by 37% (p = 0.02) and by 55% (p = 0.0003) after administration of Immulina® (200 mg and 400 mg per day, respectively) for seven days.
  • The mRNA expression of the NK- and T-cell marker perforin increased by 75% (p = 0.008) after administration of 400 mg Immulina® per day.
  • In summary, two independent studies showed enhancement of NK cell activity following administration of Immulina® for seven days.
  • [MeSH-major] Adjuvants, Immunologic / pharmacology. Killer Cells, Natural / drug effects. Leukemia, Erythroblastic, Acute / drug therapy. Lipoproteins / pharmacology. Lymphocyte Activation / drug effects. Plant Extracts / pharmacology. Spirulina / chemistry
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Phytogenic / pharmacology. Antineoplastic Agents, Phytogenic / therapeutic use. Biomarkers / metabolism. Cell Line, Tumor. Cross-Over Studies. Dietary Supplements. Dose-Response Relationship, Drug. Double-Blind Method. Female. Humans. Leukocytes, Mononuclear / drug effects. Male. Middle Aged. NK Cell Lectin-Like Receptor Subfamily K / genetics. NK Cell Lectin-Like Receptor Subfamily K / metabolism. Perforin / genetics. Perforin / metabolism. Phytotherapy. Pilot Projects. RNA, Messenger / metabolism. Reference Values. T-Lymphocytes. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 20560112.001).
  • [ISSN] 1439-0221
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers; 0 / Lipoproteins; 0 / NK Cell Lectin-Like Receptor Subfamily K; 0 / Plant Extracts; 0 / RNA, Messenger; 126465-35-8 / Perforin
  •  go-up   go-down


43. Mirault ME, Boucher P, Tremblay A: Nucleotide-resolution mapping of topoisomerase-mediated and apoptotic DNA strand scissions at or near an MLL translocation hotspot. Am J Hum Genet; 2006 Nov;79(5):779-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The emergence of therapy-related acute myeloid leukemia (t-AML) has been associated with DNA topoisomerase II (TOP2)-targeted drug treatments and chromosomal translocations frequently involving the MLL, or ALL-1, gene.
  • We report the first genomic map integrating translocation breakpoints and topoisomerase I, TOP2, and apoptotic DNA cleavage sites at nucleotide resolution across an MLL region harboring a t-AML translocation hotspot.
  • The localization and remarkable clustering of the t-AML breakpoints cannot be explained simply by the DNA cleavage patterns but might result from potential interactions between TOP2 poisoning, apoptotic DNA cleavage, and DNA repair attempts at specific sites of higher-order chromatin structure in apoptosis-evading cells.
  • [MeSH-major] DNA Breaks. DNA Topoisomerases, Type II / metabolism. Myeloid-Lymphoid Leukemia Protein / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1994 May 15;83(10):2780-6 [8180374.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2327-30 [8162575.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):257-67 [8558207.001]
  • [Cites] Blood. 1996 Mar 1;87(5):1912-22 [8634439.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2649-58 [8639880.001]
  • [Cites] Cell. 1996 Jun 14;85(6):853-61 [8681380.001]
  • [Cites] Br J Haematol. 1996 Jun;93(4):966-72 [8703835.001]
  • [Cites] Annu Rev Biochem. 1996;65:635-92 [8811192.001]
  • [Cites] Mol Biotechnol. 1996 Jun;5(3):281-8 [8837035.001]
  • [Cites] Cell. 1997 Feb 7;88(3):375-84 [9039264.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):4070-9 [9199342.001]
  • [Cites] J Biol Chem. 1997 Oct 17;272(42):26441-7 [9334220.001]
  • [Cites] Nucleic Acids Res. 1998 Apr 1;26(7):1807-11 [9512556.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):233-55 [9748598.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3793-803 [9808573.001]
  • [Cites] J Mol Biol. 1999 Jan 15;285(2):545-54 [9878428.001]
  • [Cites] Annu Rev Genet. 1998;32:495-519 [9928489.001]
  • [Cites] Oncogene. 1999 Aug 19;18(33):4663-71 [10467413.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50499-504 [15448130.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):449-54 [15626757.001]
  • [Cites] Br J Haematol. 2000 Apr;109(1):13-23 [10848777.001]
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1671-9 [10861294.001]
  • [Cites] Curr Biol. 2000 Jul 27-Aug 10;10(15):923-6 [10959840.001]
  • [Cites] Methods Mol Biol. 2001;148:175-219 [11357585.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4550-5 [11389089.001]
  • [Cites] Oncogene. 2001 May 24;20(23):2900-7 [11420702.001]
  • [Cites] Biochemistry. 2001 Jul 27;40(28):8410-8 [11444988.001]
  • [Cites] Nucleic Acids Res. 2001 Aug 15;29(16):E83 [11504891.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9802-7 [11493704.001]
  • [Cites] Apoptosis. 2002 Apr;7(2):173-7 [11865202.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):245-50 [11902580.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Apr;33(4):331-45 [11921269.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4568-73 [11930009.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1107-17 [12453418.001]
  • [Cites] J Biol Chem. 2003 Feb 28;278(9):7406-12 [12473657.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Apr;36(4):393-401 [12619163.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1377-81 [12649202.001]
  • [Cites] J Biol Chem. 2003 May 30;278(22):20303-12 [12660252.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2003 Jul;3(4):271-90 [12769773.001]
  • [Cites] Oncogene. 2003 Nov 20;22(52):8448-59 [14627986.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27302-14 [15082714.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33968-75 [15178684.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Nov;41(3):257-65 [15334549.001]
  • [Cites] Cancer Res. 1985 Jul;45(7):3106-12 [3839166.001]
  • [Cites] Biochemistry. 1988 Nov 29;27(24):8861-9 [2853972.001]
  • [Cites] Cancer Res. 1989 Sep 15;49(18):5077-82 [2548710.001]
  • [Cites] Annu Rev Biochem. 1989;58:351-75 [2549853.001]
  • [Cites] Biochemistry. 1989 Jul 25;28(15):6157-60 [2551366.001]
  • [Cites] Nucleic Acids Res. 1990 Aug 11;18(15):4553-9 [2167470.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7654-8 [1652758.001]
  • [Cites] Mol Cell Biol. 1991 Oct;11(10):4973-84 [1656219.001]
  • [Cites] EMBO J. 1992 Feb;11(2):705-16 [1311255.001]
  • [Cites] Nucleic Acids Res. 1994 Jun 25;22(12):2311-7 [8036159.001]
  • (PMID = 17033956.001).
  • [ISSN] 0002-9297
  • [Journal-full-title] American journal of human genetics
  • [ISO-abbreviation] Am. J. Hum. Genet.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ U04737; OMIM/ 159555
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 9007-49-2 / DNA; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 5.99.1.3 / DNA Topoisomerases, Type II
  • [Other-IDs] NLM/ PMC1698565
  •  go-up   go-down


44. Rosen DB, Minden MD, Kornblau SM, Cohen A, Gayko U, Putta S, Woronicz J, Evensen E, Fantl WJ, Cesano A: Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP). PLoS One; 2010;5(10):e13543
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).
  • BACKGROUND: Molecular characterization of the FMS-like tyrosine kinase 3 receptor (FLT3) in cytogenetically normal acute myeloid leukemia (AML) has recently been incorporated into clinical guidelines based on correlations between FLT3 internal tandem duplications (FLT3-ITD) and decreased disease-free and overall survival.
  • METHODOLOGY/PRINCIPAL FINDINGS: Using single cell network profiling (SCNP), cells were treated with extracellular modulators and their functional responses were quantified by multiparametric flow cytometry.
  • Intracellular signaling responses were compared between healthy bone marrow myeloblasts (BMMb) and AML leukemic blasts characterized as FLT3 wild type (FLT3-WT) or FLT3-ITD.
  • [MeSH-major] Leukemia, Myeloid, Acute / metabolism. Signal Transduction. fms-Like Tyrosine Kinase 3 / metabolism


45. Yassin ER, Sarma NJ, Abdul-Nabi AM, Dombrowski J, Han Y, Takeda A, Yaseen NR: Dissection of the transformation of primary human hematopoietic cells by the oncogene NUP98-HOXA9. PLoS One; 2009 Aug 21;4(8):e6719
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NUP98-HOXA9 is the prototype of a group of oncoproteins associated with acute myeloid leukemia.
  • In order to determine the relative contributions of the NUP98 and HOXA9 portions to the transforming ability of NUP98-HOXA9, the effects of NUP98-HOXA9 on primary human CD34+ cells were dissected and compared to those of wild-type HOXA9.
  • Taken together, these results suggest that the effects of NUP98-HOXA9 on gene transcription and cell transformation are mediated by at least two distinct mechanisms: one that involves promoter binding through the homeodomain with direct transcriptional activation, and another that depends predominantly on the NUP98 moiety and does not involve direct DNA binding.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1990 May;87(9):3584-8 [2333304.001]
  • [Cites] Cell. 1989 Jan 13;56(1):77-84 [2642744.001]
  • [Cites] Cell. 1994 Jul 29;78(2):211-23 [8044836.001]
  • [Cites] Annu Rev Biochem. 1994;63:487-526 [7979246.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1769-73 [7878057.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):154-8 [8563753.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):159-67 [8563754.001]
  • [Cites] J Biol Chem. 1997 Mar 28;272(13):8198-206 [9079637.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4451-6 [9114010.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):764-76 [9858599.001]
  • [Cites] J Cell Biol. 1999 Apr 19;145(2):237-54 [10209021.001]
  • [Cites] Leukemia. 1999 May;13(5):687-98 [10374871.001]
  • [Cites] Blood. 1999 Jul 15;94(2):741-7 [10397741.001]
  • [Cites] Mol Cell Biol. 1999 Nov;19(11):7577-88 [10523646.001]
  • [Cites] Int J Cancer. 2005 Apr 20;114(4):634-8 [15609330.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12359-70 [15681849.001]
  • [Cites] Exp Hematol. 2005 Jul;33(7):719-37 [15963848.001]
  • [Cites] Oncogene. 2005 Sep 22;24(42):6418-31 [16007190.001]
  • [Cites] Blood. 2005 Nov 1;106(9):2952-61 [16076873.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):130-40 [16491072.001]
  • [Cites] Leukemia. 2006 Apr;20(4):696-706 [16467868.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4584-90 [16651408.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6628-37 [16818636.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11781-91 [17178874.001]
  • [Cites] Mol Cell Proteomics. 2007 Feb;6(2):272-82 [17079785.001]
  • [Cites] Nat Cell Biol. 2007 Jul;9(7):804-12 [17589499.001]
  • [Cites] Subcell Biochem. 2007;42:93-126 [17612047.001]
  • [Cites] PLoS One. 2007;2(8):e768 [17712416.001]
  • [Cites] Exp Hematol. 2007 Sep;35(9):1321-32 [17637499.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8051-7 [17804716.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6766-76 [17934484.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5672-82 [18388181.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Aug 8;372(4):629-33 [18503747.001]
  • [Cites] Curr Pharm Des. 2008;14(21):2051-60 [18691115.001]
  • [Cites] Leuk Lymphoma. 2008 Aug;49(8):1452-62 [18608871.001]
  • [Cites] Oncogene. 2008 Oct 9;27(46):6056-67 [18604245.001]
  • [Cites] Drug Resist Updat. 2008 Dec;11(6):210-8 [18951834.001]
  • [Cites] J Cell Mol Med. 2009 Jan;13(1):136-46 [18363832.001]
  • [Cites] Hum Mol Genet. 2009 Apr 15;18(8):1464-70 [19228774.001]
  • [Cites] J Pathol. 2009 Jun;218(2):201-9 [19235837.001]
  • [Cites] Leukemia. 1999 Dec;13(12):1993-9 [10602420.001]
  • [Cites] Mol Cell Biol. 2000 May;20(9):3274-85 [10757811.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Aug 28;275(2):652-60 [10964718.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):31289-96 [10875935.001]
  • [Cites] EMBO J. 2001 Feb 1;20(3):350-61 [11157742.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):10453-62 [11124936.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(8):2659-70 [11283246.001]
  • [Cites] Leukemia. 2002 Feb;16(2):186-95 [11840284.001]
  • [Cites] Oncogene. 2002 Jun 20;21(27):4247-56 [12082612.001]
  • [Cites] J Cell Physiol. 2003 Mar;194(3):237-55 [12548545.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1744-51 [12393469.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2450-5 [12604785.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4529-38 [12543865.001]
  • [Cites] Trends Biochem Sci. 2003 May;28(5):267-75 [12765839.001]
  • [Cites] J Biol Chem. 2004 Jan 9;279(2):866-75 [14561764.001]
  • [Cites] EMBO J. 2004 Mar 10;23(5):1155-65 [14976548.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1605-16 [15084693.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1127-36 [15100157.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(17):7779-94 [15314183.001]
  • [Cites] Exp Cell Res. 2004 Oct 15;300(1):84-93 [15383317.001]
  • [Cites] Oncogene. 1992 Feb;7(2):323-9 [1549353.001]
  • (PMID = 19696924.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL082549; United States / NCI NIH HHS / CA / T32 CA009547; United States / NCI NIH HHS / CA / P30 CA91842; United States / NHLBI NIH HHS / HL / K02 HL084179; United States / NCI NIH HHS / CA / P30 CA091842
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Homeodomain Proteins; 0 / Nuclear Pore Complex Proteins; 0 / Nup98 protein, human; 0 / homeobox protein HOXA9
  • [Other-IDs] NLM/ PMC2725295
  •  go-up   go-down


46. Nguyen-Khac F, Lesty C, Eclache V, Couronné L, Kosmider O, Andrieux J, Collonge-Rame MA, Penther D, Lafage M, Bilhou-Nabera C, Chapiro E, Mozziconacci MJ, Mugneret F, Gachard N, Nadal N, Lippert E, Struski S, Dastugue N, Cabrol C, Bernard OA, Groupe Francophone de Cytogénétique Hématologique: Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations. Genes Chromosomes Cancer; 2010 Oct;49(10):919-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Evolution to myelofibrosis (MF), acute myeloid leukemia or myelodysplastic syndrome (AML/MDS) may occur over time in myeloproliferative neoplasms (MPN) patients most likely due to the acquisition of additional mutations.
  • The Groupe Francophone de cytogenetique hematologique (GFCH) has collected and reviewed 82 patients with transformation of MPN (66 AML/MDS and 16 MF).
  • Some specific chromosomal abnormalities occurred together, for example -5/del(5q) and -17/del(17p) (P = 0.0007).
  • In multivariate analysis, two factors were independently associated with an inferior overall survival (OS); AML/MDS transformation (P < 0.0001) and -5/del(5q) abnormality (P = 0.02).
  • We detected 24/40 (60%) JAK2V617F and 8/25 (32%) TET2 mutations in samples following transformation, ranging from wild-type to mutated forms of both genes.
  • The mutated and wild-type forms of the genes were not found to be associated with a specific chromosomal abnormality.
  • There was no evidence that JAK2 or TET2 mutations were associated with the type of MPN transformation, whereas the type of cytogenetic abnormalities were strongly linked, perhaps indicating that they play a specific role in the transformation process.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Chromosome Aberrations. DNA-Binding Proteins / genetics. Janus Kinase 2 / genetics. Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / genetics. Mutation / genetics. Proto-Oncogene Proteins / genetics

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629097.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 0 / TET2 protein, human; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


47. Truong QA, Siegel E, Karakas M, Januzzi JL Jr, Bamberg F, Mahabadi AA, Dasdemir S, Brady TJ, Bergmann A, Kunde J, Nagurney JT, Hoffmann U, Koenig W: Relation of natriuretic peptides and midregional proadrenomedullin to cardiac chamber volumes by computed tomography in patients without heart failure: from the ROMICAT Trial. Clin Chem; 2010 Apr;56(4):651-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined associations between amino-terminal pro-B-type natriuretic peptide (NT-proBNP), midregional pro-A-type natriuretic peptide (MR-proANP), and midregional proadrenomedullin (MR-proADM) concentrations and cardiac chamber volumes in chest pain patients without heart failure by use of computed tomography (CT).

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 2000 Apr;21(2):138-67 [10782362.001]
  • [Cites] J Intern Med. 2010 Jan;267(1):119-29 [19570053.001]
  • [Cites] Circulation. 2003 May 6;107(17):2207-12 [12695291.001]
  • [Cites] Heart. 2003 Jul;89(7):745-51 [12807847.001]
  • [Cites] Clin Chem. 2004 Jan;50(1):234-6 [14709661.001]
  • [Cites] J Am Coll Cardiol. 2004 Jan 7;43(1):55-60 [14715184.001]
  • [Cites] Peptides. 2004 Aug;25(8):1369-72 [15350706.001]
  • [Cites] Nutrition. 1989 Sep-Oct;5(5):303-11; discussion 312-3 [2520314.001]
  • [Cites] Endocrinology. 1993 May;132(5):1961-70 [8477647.001]
  • [Cites] Lancet. 1993 May 1;341(8853):1105-9 [8097801.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Apr 30;192(2):553-60 [8387282.001]
  • [Cites] FEBS Lett. 1994 Jan 24;338(1):6-10 [8307158.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Jun 30;201(3):1160-6 [8024557.001]
  • [Cites] Circulation. 1994 Jul;90(1):195-203 [8025996.001]
  • [Cites] J Clin Invest. 1996 May 15;97(10):2370-6 [8636418.001]
  • [Cites] Ann Intern Med. 1999 Mar 16;130(6):461-70 [10075613.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1823-9 [16099941.001]
  • [Cites] Clin Chem. 2006 May;52(5):827-31 [16543387.001]
  • [Cites] J Am Coll Cardiol. 2006 Sep 19;48(6):1217-24 [16979009.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2631-9 [17182988.001]
  • [Cites] J Card Fail. 2007 Feb;13(1):42-9 [17339002.001]
  • [Cites] J Am Coll Cardiol. 2007 Apr 10;49(14):1525-32 [17418290.001]
  • [Cites] J Am Coll Cardiol. 2007 Nov 13;50(20):1973-80 [17996563.001]
  • [Cites] Clin Biochem. 2008 Mar;41(4-5):222-6 [18035345.001]
  • [Cites] Clin Chem Lab Med. 2008;46(2):204-11 [18076360.001]
  • [Cites] Clin Chim Acta. 2008 Jun;392(1-2):41-5 [18387360.001]
  • [Cites] J Am Coll Cardiol. 2008 May 13;51(19):1857-64 [18466800.001]
  • [Cites] Eur Radiol. 2008 Aug;18(8):1625-34 [18446346.001]
  • [Cites] Am J Clin Pathol. 2008 Aug;130(2):305-11 [18628102.001]
  • [Cites] Int J Cardiol. 2008 Aug 18;128(2):244-9 [17673312.001]
  • [Cites] Circ J. 2008 Nov;72(11):1777-86 [18832779.001]
  • [Cites] J Cardiovasc Comput Tomogr. 2009 Mar-Apr;3(2):80-7 [19332340.001]
  • [Cites] J Am Coll Cardiol. 2009 May 5;53(18):1642-50 [19406338.001]
  • [Cites] J Am Coll Cardiol. 2009 May 12;53(19):1783-90 [19422985.001]
  • [Cites] Regul Pept. 2009 Jun 5;155(1-3):33-8 [19328828.001]
  • [Cites] JAMA. 2009 Jul 1;302(1):49-57 [19567439.001]
  • [Cites] J Am Coll Cardiol. 2009 Jul 21;54(4):357-64 [19608034.001]
  • [Cites] Heart Fail Clin. 2009 Oct;5(4):489-500 [19631174.001]
  • [Cites] Heart. 2003 Feb;89(2):150-4 [12527664.001]
  • (PMID = 20185624.001).
  • [ISSN] 1530-8561
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / T32HL076136; United States / NHLBI NIH HHS / HL / L30 HL093806-01; United States / NHLBI NIH HHS / HL / T32 HL076136; United States / NHLBI NIH HHS / HL / L30HL093896; United States / NHLBI NIH HHS / HL / R01 HL080053; United States / NHLBI NIH HHS / HL / L30 HL093806; United States / NHLBI NIH HHS / HL / K23 HL098370; United States / NHLBI NIH HHS / HL / HL093806-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Protein Precursors; 0 / proadrenomedullin; 114471-18-0 / Natriuretic Peptide, Brain; 148498-78-6 / Adrenomedullin
  • [Other-IDs] NLM/ NIHMS251716; NLM/ PMC2997388
  •  go-up   go-down


48. Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, Birenbaum M, Bakhanashvili M, Yerushalmi R, Luria D, Lahav M: Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer; 2005 May 23;92(10):1881-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines.
  • It has proved beneficial in treating patients with chronic myeloid leukaemia (CML).
  • The activity of IM in the blastic crisis of CML and against various myeloma cell lines suggests that this drug may also target other cellular components.
  • In the light of the important role of telomerase in malignant transformation, we evaluated the effect of IM on telomerase activity (TA) and regulation in various malignant cell lines.
  • Imatinib mesylate caused a dose-dependent inhibition of TA (up to 90% at a concentration of 15 microM IM) in c-kit-expressing SK-N-MC (Ewing sarcoma), SK-MEL-28 (melanoma), RPMI 8226 (myeloma), MCF-7 (breast cancer) and HSC 536/N (Fanconi anaemia) cells as well as in ba/F3 (murine pro-B cells), which do not express c-kit, BCR-ABL or PDGF-R.
  • The inhibition of proliferation was associated with a decrease in the S-phase of the cell cycle and an accumulation of cells in the G2/M phase.
  • This study demonstrates an additional cellular target of IM, not necessarily mediated via known tyrosine kinases, that causes inhibition of TA and cell proliferation.
  • [MeSH-minor] Animals. Benzamides. Cell Proliferation. Dose-Response Relationship, Drug. Down-Regulation. Fanconi Anemia / pathology. Humans. Imatinib Mesylate. Mice. Protein-Tyrosine Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / pharmacology. Tumor Cells, Cultured


49. Godschalk PC, Gilbert M, Jacobs BC, Kramers T, Tio-Gillen AP, Ang CW, Van den Braak N, Li J, Verbrugh HA, Van Belkum A, Endtz HP: Co-infection with two different Campylobacter jejuni strains in a patient with the Guillain-Barré syndrome. Microbes Infect; 2006 Jan;8(1):248-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Consequently, not all C. jejuni strains isolated from the faeces of a GBS patient are involved in the pathogenesis of GBS per se.
  • Furthermore, this is the first report in which cross-reactivity of antibodies to asialo-GM2 and to the LOS of a C. jejuni strain from a GBS patient has been demonstrated.


50. Gaukrodger N, Mayosi BM, Imrie H, Avery P, Baker M, Connell JM, Watkins H, Farrall M, Keavney B: A rare variant of the leptin gene has large effects on blood pressure and carotid intima-medial thickness: a study of 1428 individuals in 248 families. J Med Genet; 2005 Jun;42(6):474-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Common polymorphisms of LEP have been associated with obesity, but their association with cardiovascular disease has been little studied.
  • We have examined the impact of both common and rare polymorphisms of the LEP gene on blood pressure (BP), subclinical atherosclerosis as measured by carotid intima-medial thickness (CIMT), and body mass index (BMI) in a large family study.
  • RESULTS: The polymorphisms typed captured all common haplotypes present at LEP.

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1997 Jun 26;387(6636):903-8 [9202122.001]
  • [Cites] Obes Res. 1997 Jan;5(1):30-5 [9061713.001]
  • [Cites] Am J Hum Genet. 1998 Jul;63(1):259-66 [9634505.001]
  • [Cites] Hum Mol Genet. 1998 Oct;7(11):1745-51 [9736776.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3239-42 [9745435.001]
  • [Cites] Hypertension. 1999 May;33(5):1111-7 [10334796.001]
  • [Cites] Am J Hum Genet. 2000 Jan;66(1):279-92 [10631157.001]
  • [Cites] Ann Hum Genet. 1999 May;63(Pt 3):227-34 [10738535.001]
  • [Cites] J Hum Hypertens. 2000 Sep;14(9):573-9 [10980589.001]
  • [Cites] Diabetes. 2000 Dec;49(12):2196-200 [11118025.001]
  • [Cites] Am J Hypertens. 2001 Feb;14(2):91-7 [11243313.001]
  • [Cites] Ann Hum Genet. 2000 Sep;64(Pt 5):391-4 [11281277.001]
  • [Cites] Hypertension. 2001 May;37(5):1236-41 [11358934.001]
  • [Cites] J Hypertens. 2001 May;19(5):871-7 [11393669.001]
  • [Cites] Mol Cell Biochem. 2001 Aug;224(1-2):53-67 [11693200.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):97-101 [11731797.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1706-9 [11926895.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jun;87(6):2909-12 [12050272.001]
  • [Cites] Nature. 2002 Aug 1;418(6897):544-8 [12110843.001]
  • [Cites] Eur Heart J. 2002 Dec;23(24):1963-71 [12473259.001]
  • [Cites] Lancet. 2002 Dec 14;360(9349):1903-13 [12493255.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):112-7 [14615386.001]
  • [Cites] Circulation. 2004 Mar 9;109(9):1089-94 [14993130.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):421-3 [15026459.001]
  • [Cites] Science. 2004 Aug 6;305(5685):869-72 [15297675.001]
  • [Cites] Am J Hum Genet. 2004 Aug;75(2):220-30 [15197684.001]
  • [Cites] Hum Mol Genet. 2004 Nov 1;13(21):2691-7 [15345705.001]
  • [Cites] Hypertension. 1989 Jun;13(6 Pt 2):884-9 [2737726.001]
  • [Cites] Lancet. 1993 May 1;341(8853):1158-9 [8097848.001]
  • [Cites] Circulation. 1993 Jul;88(1):20-8 [8319334.001]
  • [Cites] Genet Epidemiol. 1993;10(3):145-58 [8349098.001]
  • [Cites] Diabetes Care. 1999 Nov;22(11):1851-7 [10546019.001]
  • [Cites] Circulation. 1995 Oct 15;92(8):2127-34 [7554192.001]
  • [Cites] Diabetes. 1996 May;45(5):679-82 [8621022.001]
  • [Cites] Nat Genet. 1998 Mar;18(3):213-5 [9500540.001]
  • (PMID = 15937081.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0400874; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Leptin
  • [Other-IDs] NLM/ PMC1736073
  •  go-up   go-down


51. Melchers F: Starting at the end. Eur J Immunol; 2007 Nov;37 Suppl 1:S125-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After more than 40 years in immunology, I have moved "backwards" over mature B cells, immature B cells, precursor B cells and lymphocyte progenitors to pluripotent hematopoietic stem cells.
  • Initially it was an intellectual exercise to trace the unknown progenitor of known B-lineage cells; now it has become an experimental approach - to de- and re-differentiate B-lineage cells to earlier differentiation stages and to other lineages of hematopoietic cells.
  • [MeSH-major] Allergy and Immunology / history. B-Lymphocytes / cytology. Cell Differentiation / immunology. Hematopoietic Stem Cells / cytology. Precursor Cells, B-Lymphoid / cytology
  • [MeSH-minor] Animals. Antibodies / immunology. Cell Lineage / immunology. History, 20th Century. Humans

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972356.001).
  • [ISSN] 0014-2980
  • [Journal-full-title] European journal of immunology
  • [ISO-abbreviation] Eur. J. Immunol.
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies
  • [Personal-name-as-subject] Melchers F
  •  go-up   go-down


52. Robien K, Bigler J, Yasui Y, Potter JD, Martin P, Storb R, Ulrich CM: Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant; 2006 Sep;12(9):973-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia.
  • Polymorphisms in these enzymes have been shown to modify toxicity of methotrexate (MTX) after hematopoietic cell transplantation.
  • In this study, we evaluated the risk of acute graft-versus-host disease (GVHD) associated with genetic variation in recipient and donor MTHFR and TS genotypes to assess whether genotype alters the efficacy of MTX in acute GVHD prophylaxis.
  • Data on the transplantation course were abstracted from medical records for 304 adults who received allogeneic hematopoietic cell transplants.
  • Multivariable logistic regression was used to assess the associations between genotypes and risk of acute GVHD.
  • Compared with recipients with the wild-type MTHFR 677CC genotype, those with the variant 677T allele showed a decreased risk of detectable acute GVHD (677CT: odds ratio, 0.8; 95% confidence interval, 0.4-1.6; 677TT: odds ratio, 0.4; 95% confidence interval, 0.2-0.8; P for trend = .01).
  • The variant MTHFR 1298C allele in recipients was associated with an increased risk of acute GVHD compared with the wild-type MTHFR 1298AA genotype (1298AC: odds ratio, 2.0; 95% confidence interval, 1.1-3.9; 1298CC: odds ratio, 3.6; 95% confidence interval, 1.0-12.7; P for trend < .01).
  • No association with risk of acute GVHD was observed for donor MTHFR genotypes or for recipient or donor TS genotypes, with the exception of an increase in acute GVHD among recipients whose donors had the TSER 3R/2R genotype (odds ratio, 3.0; 95% confidence interval, 1.3-7.2).
  • These findings indicate that host, but not donor, MTHFR genotypes modify the risk of acute GVHD in recipients receiving MTX, in a manner consistent with our previously reported associations between MTHFR genotypes and MTX toxicity.
  • Alternatively, the systemic folate environment, regulated by host tissues, might influence donor T-cell growth and activity.
  • [MeSH-major] Graft vs Host Disease / genetics. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Living Donors. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Thymidylate Synthase / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Cohort Studies. Enhancer Elements, Genetic / genetics. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Microsatellite Repeats / genetics. Middle Aged. Polymorphism, Single Nucleotide. Predictive Value of Tests. Retrospective Studies. Risk Factors


53. Peterson LF, Wang Y, Lo MC, Yan M, Kanbe E, Zhang DE: The multi-functional cellular adhesion molecule CD44 is regulated by the 8;21 chromosomal translocation. Leukemia; 2007 Sep;21(9):2010-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 8;21 translocation is a common chromosomal abnormality in acute myeloid leukemia (AML).
  • We recently identified a naturally occurring leukemogenic splice variant, AML1-ETO9a (acute myeloid leukemia-1 transcription factor and the eight-twenty-one corepressor-9a), of t(8;21).
  • To understand the leukemic potential of AML1-ETO9a, we performed microarray analysis with the murine multipotential hematopoietic FDCP-mix A4 cell line.
  • CD44 is a type I transmembrane protein and functions as the major cellular adhesion molecule for hyaluronic acid, a component of the extracellular matrix.
  • CD44 is expressed in most human cell types and is implicated in myeloid leukemia pathogenesis.
  • In addition, in the AML1-ETO9a leukemia mouse model CD44 is regulated in a cell context-dependent manner.
  • Thus, our observations suggest that AML1-ETO and its splice variant AML1-ETO9a are able to regulate the expression of the CD44 gene, linking the 8;21 translocation to the regulation of a cell adhesion molecule that is involved in the growth and maintenance of the AML blast/stem cells.
  • [MeSH-major] Antigens, CD44 / genetics. Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Leukemia, Myeloid / genetics. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Alternative Splicing. Animals. Cell Differentiation. Cell Division. Cell Survival. Core Binding Factor Alpha 2 Subunit / genetics. Gene Expression Regulation, Leukemic. Humans. K562 Cells. Mice. Neoplastic Stem Cells / cytology. Neoplastic Stem Cells / physiology. Oligonucleotide Array Sequence Analysis. Oncogene Proteins, Fusion / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657222.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA104509
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Antigens, CD44; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


54. Kraus M, Rückrich T, Reich M, Gogel J, Beck A, Kammer W, Berkers CR, Burg D, Overkleeft H, Ovaa H, Driessen C: Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia; 2007 Jan;21(1):84-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
  • Applying a functional proteomics approach, we used a recently developed activity-based, cell-permeable proteasome-specific probe that for the first time allows differential visualization of individual active proteasomal subunits in intact primary cells.
  • In primary leukemia samples, we observed remarkable variability in the amounts of active beta1/1i-, beta2/2i- and beta5/5i-type of subunits, contrasting with their constant protein expression.
  • Bortezomib inhibited beta5- and beta1-type, but to a lesser extend beta2-type of subunits in live primary cells in vitro and in vivo.
  • When we adapted the bortezomib-sensitive human acute myeloid leukemia cell line HL-60 to bortezomib 40 nM (HL-60a), proteasomal activity profiling revealed an upregulation of active subunits, and residual beta1/beta5-type of activity could be visualized in the presence of bortezomib 20 nM, in contrast to control cells.
  • In a panel of cell lines from hematologic malignancies, the ratio between beta2-type and (beta1 + beta5)-type of active proteasomal polypeptides mirrored different degrees of bortezomib sensitivity.
  • We thus conclude that the proteasomal activity profile varies in primary leukemia cells, and that the pattern of proteasomal subunit activity influences the sensitivity of hematologic malignancies toward bortezomib.
  • [MeSH-minor] Animals. Bortezomib. Cell Line, Tumor. Drug Screening Assays, Antitumor. Humans. Leukemia / drug therapy. Leukemia / enzymology. Mice. Protease Inhibitors / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17024115.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


55. Akahane K, Inukai T, Zhang X, Hirose K, Kuroda I, Goi K, Honna H, Kagami K, Nakazawa S, Endo K, Kubota T, Yagita H, Koyama-Okazaki T, Sugita K: Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis. Exp Hematol; 2010 Oct;38(10):885-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis.
  • OBJECTIVE: Cytotoxic ligands are involved in tumor immunity and graft-vs.-leukemia effect after allogeneic stem cell transplantation for leukemia.
  • To clarify the susceptibility of T-cell acute lymphoblastic leukemia (T-ALL) to tumor immunity, sensitivity to recombinant human soluble Fas ligand (rhsFasL) and tumor necrosis factor-related apoptosis-inducing ligand (rhsTRAIL) was determined.
  • MATERIALS AND METHODS: Sensitivity to rhsFasL and rhsTRAIL and cell surface expression of their receptors were tested in T-ALL cell lines (n = 7) and patients' samples (n = 17) and compared with those in B-precursor ALL cell lines (n = 30).
  • Expression of components of the death-inducing signaling complex and the TRAIL receptor genes (DR4/DR5), and the methylation status and promoter activity of the DR4/DR5 gene were tested in T-ALL cell lines.
  • RESULTS: T-ALL cell lines showed higher level of Fas expression and higher sensitivity to rhsFasL than did B-precursor ALL cell lines.
  • Despite comparable expression of components of death-inducing signaling complex, cell lines and patients' samples of T-ALL showed TRAIL-resistance associated with low cell surface expression of DR4/DR5.
  • Gene expression of DR4/DR5 in T-ALL cell lines was significantly lower than that in B-precursor ALL cell lines, and the methylation status of the gene promoter in T-ALL cell lines was associated with the gene expression level at least for DR4.
  • [MeSH-major] Apoptosis / drug effects. Cell Proliferation / drug effects. Fas Ligand Protein / pharmacology. TNF-Related Apoptosis-Inducing Ligand / pharmacology
  • [MeSH-minor] Antigens, CD95 / metabolism. Cell Line, Tumor. Cells, Cultured. DNA Methylation / drug effects. Dose-Response Relationship, Drug. Drug Resistance. Flow Cytometry. Gene Expression / drug effects. Humans. Immunoblotting. Jurkat Cells. Luciferases / genetics. Luciferases / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Promoter Regions, Genetic / genetics. Receptors, TNF-Related Apoptosis-Inducing Ligand / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20670671.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / FAS protein, human; 0 / Fas Ligand Protein; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / TNF-Related Apoptosis-Inducing Ligand; EC 1.13.12.- / Luciferases
  •  go-up   go-down


56. Forester CM, Braunreiter CL, Yaish H, Hedlund GL, Afify Z: Tumefactive intracranial presentation of precursor B-cell acute lymphoblastic leukemia. Pediatr Radiol; 2009 Nov;39(11):1230-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumefactive intracranial presentation of precursor B-cell acute lymphoblastic leukemia.
  • In children, leukemia is the most common malignancy, and approximately 75% of leukemias are acute lymphoblastic leukemia (ALL).
  • Central nervous system leukemia is found at diagnosis in fewer than 5% of children with ALL.
  • Leukemic intracranial masses have been described with acute myeloid leukemia, but ALL presenting as a mass lesion is rare.
  • We describe a unique case of an intracranial confirmed precursor B cell (pre-B) ALL mass in a 13-year-old girl that was diagnosed by brain CT, MRI and cerebral angiography, and confirmed by biopsy.
  • [MeSH-major] Brain Neoplasms / diagnosis. Cerebral Angiography / methods. Magnetic Resonance Imaging / methods. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Tomography, X-Ray Computed / methods


57. Adjouadi M, Ayala M, Cabrerizo M, Zong N, Lizarraga G, Rossman M: Classification of leukemia blood samples using neural networks. Ann Biomed Eng; 2010 Apr;38(4):1473-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification of leukemia blood samples using neural networks.
  • Pattern recognition applied to blood samples for diagnosing leukemia remains an extremely difficult task which frequently leads to misclassification errors due in large part to the inherent problem of data overlap.
  • A novel artificial neural network (ANN) algorithm is proposed for optimizing the classification of multidimensional data, focusing on acute leukemia samples.
  • The programming tool established around the ANN architecture focuses on the classification of normal vs. abnormal blood samples, namely acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML).
  • With this type of accuracy, this programming tool provides information to medical doctors in the form of diagnostic references for the specific disease states that are considered for this study.
  • The results obtained prove that a neural network classifier can perform remarkably well for this type of flow-cytometry data.
  • [MeSH-major] Algorithms. Blood Cell Count / methods. Diagnosis, Computer-Assisted / methods. Flow Cytometry / methods. Leukemia / blood. Leukemia / pathology. Neural Networks (Computer). Pattern Recognition, Automated / methods

  • MedlinePlus Health Information. consumer health - Blood Count Tests.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20013155.001).
  • [ISSN] 1573-9686
  • [Journal-full-title] Annals of biomedical engineering
  • [ISO-abbreviation] Ann Biomed Eng
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


58. Herrera L, Bostrom B, Gore L, Sandler E, Lew G, Schlegel PG, Aquino V, Ghetie V, Vitetta ES, Schindler J: A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2009 Dec;31(12):936-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia.
  • BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common cancer in children.
  • Preclinical data have demonstrated which Combotox is effective in killing pre-B-ALL cell lines and cells from patients with pre-B ALL.
  • CONCLUSIONS: Combotox can be safely administered to children with refractory leukemia.
  • [MeSH-major] Immunotoxins / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Ricin / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19875969.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD19; 0 / CD22 protein, human; 0 / Immunotoxins; 0 / Sialic Acid Binding Ig-like Lectin 2; 9009-86-3 / Ricin
  •  go-up   go-down


59. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS: Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother; 2009 Sep;53(9):3690-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A detailed kinetic characterization demonstrated that amino acid substitutions in Fks1p and Fks2p reduced drug sensitivity in mutant 1,3-beta-D-glucan synthase by 2 to 3 log orders relative to that in wild-type enzyme.
  • However, when MIC determinations were performed in the presence of 50% serum, all C. glabrata fks mutants showed MICs of > or = 2 microg/ml for the three echinocandin drugs.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Mycol. 2001;39 Suppl 1:55-66 [11800269.001]
  • [Cites] J Clin Microbiol. 2007 Jan;45(1):70-5 [17079501.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Oct;46(10):3268-72 [12234857.001]
  • [Cites] J Clin Microbiol. 2002 Oct;40(10):3551-7 [12354845.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Expert Opin Investig Drugs. 2003 Aug;12(8):1313-33 [12882619.001]
  • [Cites] Drug Resist Updat. 2003 Aug;6(4):197-218 [12962685.001]
  • [Cites] Lancet. 2003 Oct 4;362(9390):1142-51 [14550704.001]
  • [Cites] J Clin Microbiol. 2003 Dec;41(12):5729-31 [14662968.001]
  • [Cites] J Clin Microbiol. 2004 Jul;42(7):3137-41 [15243072.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Aug;48(8):3107-11 [15273127.001]
  • [Cites] Clin Infect Dis. 2004 Aug 1;39(3):309-17 [15306996.001]
  • [Cites] Rev Iberoam Micol. 2003 Dec;20(4):121-36 [15456349.001]
  • [Cites] Antimicrob Agents Chemother. 1991 Jan;35(1):99-103 [1826595.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12907-11 [7528927.001]
  • [Cites] Clin Microbiol Rev. 1999 Jan;12(1):80-96 [9880475.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Aug;49(8):3264-73 [16048935.001]
  • [Cites] J Clin Microbiol. 2005 Aug;43(8):4107-11 [16081957.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jun;7(6):415-25 [16723977.001]
  • [Cites] Antimicrob Agents Chemother. 2007 May;51(5):1616-20 [17307976.001]
  • [Cites] Antimicrob Agents Chemother. 2007 Jun;51(6):2253-6 [17420211.001]
  • [Cites] Drug Resist Updat. 2007 Jun;10(3):121-30 [17569573.001]
  • [Cites] Antimicrob Agents Chemother. 2007 Nov;51(11):4214-6 [17785512.001]
  • [Cites] J Clin Microbiol. 2008 Feb;46(2):551-9 [18094129.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jun;52(6):2263-5 [18378714.001]
  • [Cites] Cancer. 2008 Jun;112(11):2493-9 [18412153.001]
  • [Cites] EMBO J. 2008 Jun 4;27(11):1585-95 [18451801.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jul;52(7):2305-12 [18443110.001]
  • [Cites] J Clin Microbiol. 2008 Aug;46(8):2620-9 [18579718.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Oct;52(10):3783-5 [18676885.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Nov;52(11):4181-3 [18794386.001]
  • [Cites] Genetics. 2008 Nov;180(3):1391-405 [18791219.001]
  • [Cites] Antimicrob Agents Chemother. 2009 Jan;53(1):112-22 [18955538.001]
  • [Cites] Int J Syst Evol Microbiol. 2006 Jan;56(Pt 1):313-7 [16403904.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Aug;50(8):2892-4 [16870797.001]
  • [Cites] J Clin Microbiol. 2006 Oct;44(10):3533-8 [17021079.001]
  • [Cites] Clin Infect Dis. 2002 Sep 1;35(5):627-30 [12173140.001]
  • (PMID = 19546367.001).
  • [ISSN] 1098-6596
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI069397; United States / NIAID NIH HHS / AI / AI069397
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Fungal Proteins; EC 2.4.1.- / Glucosyltransferases; EC 2.4.1.34 / 1,3-beta-glucan synthase
  • [Other-IDs] NLM/ PMC2737881
  •  go-up   go-down


60. Moberg C, Alderling M, Meding B: Hand eczema and quality of life: a population-based study. Br J Dermatol; 2009 Aug;161(2):397-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hand eczema is a common disease in the population and is of interest from a public health perspective.
  • The EQ-5D index for hand eczema was of the same size as for psoriasis and asthma, all common diseases with an impact on public health.

  • Genetic Alliance. consumer health - Eczema.
  • MedlinePlus Health Information. consumer health - Eczema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302069.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


61. Toungoussova OS, Mariandyshev AO, Bjune G, Caugant DA, Sandven P: Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs. Eur J Clin Microbiol Infect Dis; 2005 Mar;24(3):202-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multidrug-resistant tuberculosis has become common all over the world, necessitating the inclusion of second-line drugs in treatment regimens.

  • Genetic Alliance. consumer health - Tuberculosis.
  • Hazardous Substances Data Bank. CAPREOMYCIN .
  • Hazardous Substances Data Bank. ETHIONAMIDE .
  • Hazardous Substances Data Bank. KANAMYCIN A .
  • Hazardous Substances Data Bank. Ofloxacin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2002 Apr 15;185(8):1197-202 [11930334.001]
  • [Cites] BMJ. 2003 Mar 15;326(7389):574 [12637401.001]
  • [Cites] J Clin Microbiol. 2002 Jun;40(6):1930-7 [12037045.001]
  • [Cites] Int J Tuberc Lung Dis. 2002 May;6(5):406-14 [12019916.001]
  • [Cites] J Clin Microbiol. 1999 Oct;37(10):3179-86 [10488174.001]
  • [Cites] Int J Tuberc Lung Dis. 2001 Mar;5(3):213-5 [11326818.001]
  • [Cites] Clin Infect Dis. 2003 Sep 1;37(5):665-72 [12942398.001]
  • [Cites] Int J Tuberc Lung Dis. 2000 Dec;4(12 Suppl 2):S194-207 [11144553.001]
  • [Cites] Lancet. 2002 Jun 8;359(9322):1980-9 [12076553.001]
  • [Cites] Clin Microbiol Rev. 1995 Oct;8(4):496-514 [8665467.001]
  • (PMID = 15742171.001).
  • [ISSN] 0934-9723
  • [Journal-full-title] European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • [ISO-abbreviation] Eur. J. Clin. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antitubercular Agents; 11003-38-6 / Capreomycin; 59-01-8 / Kanamycin; A4P49JAZ9H / Ofloxacin; OAY8ORS3CQ / Ethionamide
  •  go-up   go-down


62. Harrison CJ: Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol; 2009 Jan;144(2):147-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia.
  • Cytogenetics has determined the incidence and prognostic significance of chromosomal abnormalities in acute lymphoblastic leukaemia (ALL).
  • Five 'hot topics' are presented in which cytogenetics and related techniques have been instrumental in understanding the role of genetics in leukaemogenesis: (i) genetic changes are integral to the biology of T-cell ALL;.
  • (ii) intrachromosomal amplification of chromosome 21 is a new recurrent abnormality in precursor-B ALL (BCP-ALL);.
  • (iv) alterations in genes involved in B-cell development and cell cycle control contribute to the pathogenesis of BCP-ALL;.
  • [MeSH-major] Chromosome Aberrations. Cytogenetic Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19006567.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 74
  •  go-up   go-down


63. Lu Y, Chen W, Chen W, Stein A, Weiss LM, Huang Q: C/EBPA gene mutation and C/EBPA promoter hypermethylation in acute myeloid leukemia with normal cytogenetics. Am J Hematol; 2010 Jun;85(6):426-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C/EBPA gene mutation and C/EBPA promoter hypermethylation in acute myeloid leukemia with normal cytogenetics.
  • Four of 53 cases displayed C/EBPA mutations, whereas 49 cases had only C/EBPA wild-type alleles.
  • In conclusion, C/EBPA mutation and promoter hypermethylation can be detected at a relatively low frequency in de novo CN-AML patients, suggesting they may contribute to leukemogenesis.
  • C/EBPA mutation appears to be seen in "high-risk" AML (FLT3/ITD+/NPM1+; FLT3/ITD+/NPM1- or FLT3/ITD-/NPM1-), while C/EBPA hypermethylation appears to be more common in AML with FLT3/ITD- /NPM1- and is not associated with C/EBPA mutation.
  • [MeSH-major] CCAAT-Enhancer-Binding Proteins / genetics. DNA Methylation. Leukemia, Myeloid / genetics. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Cell Transformation, Neoplastic / genetics. DNA Mutational Analysis. Female. Humans. Male. Middle Aged. Nuclear Proteins / genetics. Risk. Young Adult. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20513120.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Proteins; 0 / CEBPA protein, human; 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


64. Chantrain CF, Jijon P, De Raedt T, Vermylen C, Poirel HA, Legius E, Brichard B: Therapy-related acute myeloid leukemia in a child with Noonan syndrome and clonal duplication of the germline PTPN11 mutation. Pediatr Blood Cancer; 2007 Jan;48(1):101-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myeloid leukemia in a child with Noonan syndrome and clonal duplication of the germline PTPN11 mutation.
  • A few months later, the patient developed acute myelomonoblastic leukemia with an additional clonal deletion of 7q.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Gene Duplication / drug effects. Germ-Line Mutation. Intracellular Signaling Peptides and Proteins / genetics. Leukemia, Myeloid, Acute / chemically induced. Leukemia, Myeloid, Acute / genetics. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / genetics. Noonan Syndrome. Protein Tyrosine Phosphatases / genetics
  • [MeSH-minor] Child, Preschool. Chromosome Deletion. Chromosomes, Human, Pair 7. Fatal Outcome. Female. Humans. Neoplasm Staging. Peripheral Blood Stem Cell Transplantation / adverse effects. Protein Tyrosine Phosphatase, Non-Receptor Type 11. Retinoblastoma / drug therapy. Retinoblastoma / genetics. Transplantation, Autologous


65. Russell T, Oliver JM, Wilson BS, Tarleton CA, Winter SS, Meng X: Differential expression of Ikaros isoforms in monozygotic twins with MLL-rearranged precursor-B acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2008 Dec;30(12):941-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of Ikaros isoforms in monozygotic twins with MLL-rearranged precursor-B acute lymphoblastic leukemia.
  • Infant leukemia associated with rearrangement of the MLL gene typically presents with high-risk clinical features.
  • Relapse is common despite aggressive therapy and perturbations in signaling pathways may contribute to disease resistance.
  • We evaluated twin 4-month-old monozygotic baby boys who presented with MLL-rearranged precursor-B acute lymphoblastic leukemia.
  • However, the dominant-negative Ik8 isoform was detected in only 1 boy, suggesting a common genetic ontogeny that was modulated by leukemic evolution.
  • [MeSH-major] Diseases in Twins / genetics. Gene Rearrangement. Ikaros Transcription Factor / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Twins, Monozygotic
  • [MeSH-minor] Acid Anhydride Hydrolases / genetics. Acute Disease. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 4 / genetics. Female. Histone-Lysine N-Methyltransferase. Humans. Infant. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics. Protein Isoforms / genetics. Translocation, Genetic. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131787.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IKZF1 protein, human; 0 / MLL protein, human; 0 / MLL-AF4 fusion protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Protein Isoforms; 0 / fragile histidine triad protein; 148971-36-2 / Ikaros Transcription Factor; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


66. Ma J, Sun H, Chen SM, Liu LX, Chen SQ, Liu YF, Xie XS, Meng XL, Deng M, Zhang QT, Li T: [Clinical features and survival analysis of patients with CD20 positive adult B-lineage acute lymphoblastic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr;18(2):477-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and survival analysis of patients with CD20 positive adult B-lineage acute lymphoblastic leukemia].
  • The aim of this study was to explore the clinical features and survival of adult patients with CD20 positive B-lineage acute lymphoblastic leukemia (B-ALL).
  • The results showed that among 119 cases, CD20 positive B-ALL accounted for 40 cases (33.61%), CD20 negative B-ALL patents accounted for 79 cases (66.39), the percentage of male patients in CD20 positive and negative groups were 72.50% and 50.63%, the leukocyte counts at diagnosis in these two groups were (27.35+/-30.29)x10(9)/L and (0.11+/-81.72)x10(9)/L, respectively, there were significant differences (p<0.05), whereas the distribution of age, infiltration of liver, spleen, lymph nodes and central nervous system, the hemoglobin and platelet levels, the expression of myeloid lineage marker, the incidence of Ph chromosome, the ratio of hyperdiploid and normal karyotype, the complete remission rate within 4 weeks, induction death rate and relapse rate and so on in CD20 positive and negative groups showed no significant differences (p>0.05).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20416193.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20
  •  go-up   go-down


67. Emadi A, Ross AE, Cowan KM, Fortenberry YM, Vuica-Ross M: A chemical genetic screen for modulators of asymmetrical 2,2'-dimeric naphthoquinones cytotoxicity in yeast. PLoS One; 2010;5(5):e10846
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Dimeric naphthoquinones (BiQ) were originally synthesized as a new class of HIV integrase inhibitors but have shown integrase-independent cytotoxicity in acute lymphoblastic leukemia cell lines suggesting their use as potential anti-neoplastic agents.
  • METHODOLOGY/PRINCIPAL FINDINGS: Exposure of wild type yeast strains to various BiQs demonstrated inhibition of yeast growth with IC(50)s in the microM range.
  • Corresponding to this, wild type yeast grown in the absence of a fermentable carbon source were particularly sensitive to BiQs, and treatment with BiQs was shown to disrupt the mitochondrial membrane potential and lead to the generation of reactive oxygen species (ROS).
  • Furthermore, baseline ROS production in BiQ sensitive mutant strains was increased compared to wild type and could be further augmented by the presence of BiQ.
  • Screens for resistance to BiQ action identified the mitochondrial external NAD(P)H dehydrogenase, NDE1, as critical to BiQ toxicity and over-expression of this gene resulted in increased ROS production and increased sensitivity of wild type yeast to BiQ.

  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2001 Dec;21(24):8483-9 [11713283.001]
  • [Cites] Free Radic Biol Med. 2000 Aug;29(3-4):246-53 [11035253.001]
  • [Cites] Methods Enzymol. 2002;350:248-57 [12073316.001]
  • [Cites] Nature. 2002 Jul 25;418(6896):387-91 [12140549.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):400-4 [12134146.001]
  • [Cites] Curr Cancer Drug Targets. 2002 Sep;2(3):227-42 [12188909.001]
  • [Cites] Free Radic Biol Med. 2002 Nov 1;33(9):1209-20 [12398929.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3345-50 [12615994.001]
  • [Cites] Yeast. 2004 Feb;21(3):241-8 [14968429.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4525-30 [15070751.001]
  • [Cites] J Org Chem. 2004 Jul 23;69(15):5128-31 [15255750.001]
  • [Cites] Bull Soc Chim Biol (Paris). 1966;48(11):1189-203 [4293716.001]
  • [Cites] Genetics. 1982 Jun;101(2):157-77 [6293912.001]
  • [Cites] Methods Enzymol. 1991;194:149-65 [1706458.001]
  • [Cites] Chem Biol Interact. 1991;80(1):1-41 [1913977.001]
  • [Cites] J Biol Chem. 1991 Nov 15;266(32):21496-503 [1718980.001]
  • [Cites] Cancer Metastasis Rev. 1993 Jun;12(2):165-76 [8375019.001]
  • [Cites] Mutat Res. 1994 Feb;317(1):25-42 [7507571.001]
  • [Cites] Gene. 1995 May 26;158(1):113-7 [7789793.001]
  • [Cites] J Bacteriol. 1998 Aug;180(16):4051-5 [9696750.001]
  • [Cites] J Biol Chem. 1998 Sep 18;273(38):24529-34 [9733747.001]
  • [Cites] FEBS Lett. 1999 Jul 9;454(3):173-6 [10431801.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3710-5 [15297299.001]
  • [Cites] PLoS Genet. 2005 Sep;1(3):e36 [16170412.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3604-9 [16505371.001]
  • [Cites] Hum Genomics. 2006 Mar;2(5):329-35 [16595077.001]
  • [Cites] Amino Acids. 2006 May;30(3):205-24 [16601927.001]
  • [Cites] Bioorg Med Chem. 2006 Aug 15;14(16):5651-65 [16737818.001]
  • [Cites] J Cell Physiol. 2006 Dec;209(3):604-10 [17001694.001]
  • [Cites] FEBS J. 2007 Mar;274(5):1328-39 [17298444.001]
  • [Cites] Mitochondrion. 2007 Jun;7 Suppl:S62-71 [17482885.001]
  • [Cites] Prog Drug Res. 2008;66:237, 239-71 [18416308.001]
  • [Cites] Anticancer Res. 2009 Jan;29(1):191-9 [19331150.001]
  • [Cites] PLoS One. 2009;4(6):e5830 [19503795.001]
  • [Cites] Br J Haematol. 2009 Nov;147(4):459-70 [19747367.001]
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5416-24 [10681517.001]
  • [Cites] Nat Genet. 2000 May;25(1):25-9 [10802651.001]
  • [Cites] Org Lett. 2002 Feb 21;4(4):521-4 [11843581.001]
  • (PMID = 20520766.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media; 0 / Naphthoquinones; 0 / Reactive Oxygen Species; 0 / Saccharomyces cerevisiae Proteins
  • [Other-IDs] NLM/ PMC2877097
  •  go-up   go-down


68. Heesch S, Goekbuget N, Stroux A, Tanchez JO, Schlee C, Burmeister T, Schwartz S, Blau O, Keilholz U, Busse A, Hoelzer D, Thiel E, Hofmann WK, Baldus CD: Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. Haematologica; 2010 Jun;95(6):942-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.
  • BACKGROUND: The role of the Wilms tumor 1 gene (WT1) in acute leukemias has been underscored by mutations found in acute myeloid leukemia identifying patients with inferior survival.
  • Furthermore, aberrant expression of WT1 in acute myeloid leukemia was associated with an increased risk of relapse.
  • No larger studies have performed a combined approach including WT1 mutation and expression analyses in acute T-lymphoblastic leukemia.
  • DESIGN AND METHODS: We analyzed the WT1 mutations and the expression status in a total of 252 consecutive adult patients with newly diagnosed T-lymphoblastic leukemia, who were registered on the GMALL 06/99 and 07/03 protocols and had sufficient material available.
  • The GMALL protocols included intensive chemotherapy as well as stem cell transplantation according to a risk-based model with indication for stem cell transplantation in first complete remission for early and mature T-lymphoblastic leukemia patients; patients with thymic T-lymphoblastic leukemia were allocated to a standard risk group and treated with intensive chemotherapy.
  • In thymic T-lymphoblastic leukemia, WT1mut patients had an inferior relapse-free survival compared to WT1 wild-type patients.
  • T-lymphoblastic leukemia patients with aberrant WT1 expression (high or negative) showed a higher relapse rate and an inferior outcome compared to patients with intermediate WT1 expression.
  • In the standard risk group of thymic T-lymphoblastic leukemia, aberrant WT1 expression was predictive for an inferior relapse-free survival as compared to patients with intermediate expression.
  • CONCLUSIONS: WT1 mutations were associated with an inferior relapse-free survival in standard risk thymic T-lymphoblastic leukemia patients.
  • Moreover, altered expression associated with inferior outcome also suggests a role of WT1 in T-lymphoblastic leukemia and the potential use of molecularly-based treatment stratification to improve outcome.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Genes, Wilms Tumor / physiology. Mutation / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Leukemia. 1995 Jun;9(6):1060-7 [7596170.001]
  • [Cites] Exp Hematol. 1997 Apr;25(4):312-20 [9131006.001]
  • [Cites] Leukemia. 1997 May;11(5):639-43 [9180285.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1217-25 [9242555.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2961-8 [9531607.001]
  • [Cites] EMBO J. 1999 Jul 15;18(14):3990-4003 [10406804.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:80-97 [15561678.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1416-23 [15920493.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4414-5 [16326981.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Leukemia. 2006 Feb;20(2):254-63 [16341043.001]
  • [Cites] Haematologica. 2006 Feb;91(2):270-1 [16461320.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1507-15 [16575000.001]
  • [Cites] Oncogene. 2006 Jul 13;25(30):4217-29 [16518414.001]
  • [Cites] Leukemia. 2007 Mar;21(3):550-1; author reply 552 [17205055.001]
  • [Cites] Leukemia. 2007 May;21(5):868-76 [17361230.001]
  • [Cites] Expert Rev Mol Med. 2007;9(14):1-17 [17524167.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Leukemia. 2008 Apr;22(4):762-70 [18185524.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1154-60 [18368072.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5429-35 [18591546.001]
  • [Cites] Blood. 2009 Jul 30;114(5):1038-45 [19494353.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3303-12 [16380455.001]
  • [Cites] EMBO J. 2001 Apr 17;20(8):1897-909 [11296223.001]
  • [Cites] Leukemia. 2001 Dec;15(12):1914-22 [11753613.001]
  • [Cites] Br J Haematol. 2002 Feb;116(2):409-20 [11841446.001]
  • [Cites] Int J Hematol. 2003 Jun;77(5):463-70 [12841384.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1589-95 [12886247.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2474-86 [14562124.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Blood. 2004 Jul 15;104(2):558-60 [15044257.001]
  • [Cites] Haematologica. 2004 Aug;89(8):926-33 [15339675.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Blood. 1989 Apr;73(5):1247-58 [2467704.001]
  • [Cites] J Biol Chem. 1994 Feb 25;269(8):6198-206 [8119964.001]
  • [Cites] Hum Mutat. 1997;9(3):209-25 [9090524.001]
  • (PMID = 20435628.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2878792
  •  go-up   go-down


69. Sabbattini P, Dillon N: The lambda5-VpreB1 locus--a model system for studying gene regulation during early B cell development. Semin Immunol; 2005 Apr;17(2):121-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The lambda5-VpreB1 locus--a model system for studying gene regulation during early B cell development.
  • The lambda5 and VpreB genes encode the components of the surrogate light-chain, which forms part of the pre-B cell receptor.
  • Activation of the genes in pro-B cells depends on the combined effects of early B cell factor (EBF) and the E2A factors E12 and E47.
  • Silencing of lambda5 expression in mature B cells occurs through the action of Ikaros on the gene promoter where it may compete for binding of EBF and initiate the formation of a silent chromatin structure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737573.001).
  • [ISSN] 1044-5323
  • [Journal-full-title] Seminars in immunology
  • [ISO-abbreviation] Semin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin Light Chains, Surrogate; 0 / Membrane Glycoproteins; 0 / Transcription Factors
  • [Number-of-references] 56
  •  go-up   go-down


70. Goei D, Flu WJ, Hoeks SE, Galal W, Dunkelgrun M, Boersma E, Kuijper R, van Kuijk JP, Winkel TA, Schouten O, Bax JJ, Poldermans D: The interrelationship between preoperative anemia and N-terminal pro-B-type natriuretic peptide: the effect on predicting postoperative cardiac outcome in vascular surgery patients. Anesth Analg; 2009 Nov;109(5):1403-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The interrelationship between preoperative anemia and N-terminal pro-B-type natriuretic peptide: the effect on predicting postoperative cardiac outcome in vascular surgery patients.
  • INTRODUCTION: N-terminal pro-B-type natriuretic peptide (NT-proBNP) predicts adverse cardiac outcome in patients undergoing vascular surgery.

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19843778.001).
  • [ISSN] 1526-7598
  • [Journal-full-title] Anesthesia and analgesia
  • [ISO-abbreviation] Anesth. Analg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Hemoglobins; 0 / Peptide Fragments; 0 / Troponin T; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


71. Shelton RJ, Clark AL, Goode K, Rigby AS, Cleland JG: The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation. Eur Heart J; 2006 Oct;27(19):2353-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation.
  • AIMS: To assess the role of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the diagnosis of major structural heart disease (MSHD) in patients with atrial fibrillation (AF) compared with those with sinus rhythm (SR) using receiver operator characteristic (ROC) analysis.
  • AF, a common finding in HF and MSHD, is also associated with raised plasma NT-proBNP.
  • [MeSH-major] Atrial Fibrillation / blood. Heart Failure / diagnosis. Natriuretic Peptide, Brain / blood. Peptide Fragments / blood
  • [MeSH-minor] Aged. Echocardiography. Female. Humans. Male. Predictive Value of Tests. Regression Analysis. Ventricular Dysfunction, Left / diagnosis


72. MacKinnon N, Ridgway J, Crowell KJ, Macdonald PM: Aluminum binding to phosphatidylcholine lipid bilayer membranes: aluminum exchange lifetimes from 31P NMR spectroscopy. Chem Phys Lipids; 2006 Feb;139(2):85-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over the temperature range from 5 to 35 degrees C all three exchange rate constants increased by roughly an order of magnitude from k approximately 1-2 to 10-14s(-1), exhibiting Arrhenius behavior with activation energies on the order of 30-45 kJ mol(-1) and correspondingly positive enthalpies of activation.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALUMINUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16336955.001).
  • [ISSN] 0009-3084
  • [Journal-full-title] Chemistry and physics of lipids
  • [ISO-abbreviation] Chem. Phys. Lipids
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Lipid Bilayers; 0 / Membranes, Artificial; 0 / Phosphatidylcholines; 0 / Phosphorus Isotopes; CPD4NFA903 / Aluminum
  •  go-up   go-down


73. Owatari S, Otsuka M, Takeshita T, Mizukami K, Suzuki S, Uozumi K, Tashiro Y, Arima N, Hanada S: Uncommon cases of immature-type CD56+ natural killer (NK)-cell neoplasms, characterized by expression of myeloid antigen of blastic NK-cell lymphoma. Int J Hematol; 2009 Mar;89(2):188-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncommon cases of immature-type CD56+ natural killer (NK)-cell neoplasms, characterized by expression of myeloid antigen of blastic NK-cell lymphoma.
  • Immature-type CD56(+) natural killer (NK)-cell neoplasms are classified as either myeloid/NK-cell precursor acute leukemia or blastic NK-cell lymphoma.
  • We identified two cases of immature-type CD56(+) NK-cell neoplasms that were not categorizable as either of these entities.
  • Cell surface markers of malignant cells showed CD4(+), CD7(-), CD13(+), CD33(+), CD34(-), CD43(+), CD56(+), cyCD68(+), and HLA-DR(+).
  • The phenotypes of tumor cells in both cases were compatible with blastic NK-cell lymphoma, except for the expression of myeloid antigen.
  • Clinical presentations of these cases showed characteristics of both blastic NK-cell lymphoma and myeloid/NK-cell precursor acute leukemia.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphoid / pathology. Leukemia, Myeloid, Acute / pathology


74. Schelonka RL, Ivanov II, Vale AM, Szymanska E, Zemlin M, Gartland GL, Schroeder HW Jr: The CDR-H3 repertoire from TdT-deficient adult bone marrow is a close, but not exact, homologue of the CDR-H3 repertoire from perinatal liver. J Immunol; 2010 Nov 15;185(10):6075-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • V(H)7183-containing VDJCμ transcripts from these cells were amplified, cloned, sequenced, and compared with transcripts from wild-type perinatal liver and adult BM.
  • What minor differences were detected in the pro-B cell stage tended to diminish with B cell maturation, suggesting strong environmental or Ag-driven pressure to achieve a specific range of V(H)DJ(H) usage regardless of the extent of N nucleotide addition.
  • However, although the patterns of V(H)DJ(H) usage in the TdT-deficient B lineage cells paralleled that of wild-type adult cells, the length distribution, global amino acid composition, and charge distribution of the CDR-H3 repertoire proved to be a close, although not exact, homologue of the CDR-H3 repertoire first expressed by late pre-B cells in the TdT-insufficient perinatal liver.
  • Thus, although differing in V(H) content, TdT-deficient mice appear to represent a good, although not perfect, model for testing the role of perinatal CDR-H3 limitations on late B cell development and Ab responses.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Immunol. 2000 Jan;94(1):24-32 [10607487.001]
  • [Cites] Immunogenetics. 2010 Oct;62(10):653-66 [20714894.001]
  • [Cites] Annu Rev Immunol. 2001;19:595-621 [11244048.001]
  • [Cites] J Immunol. 2001 Jul 1;167(1):257-63 [11418657.001]
  • [Cites] J Immunol. 2001 Sep 15;167(6):3486-93 [11544342.001]
  • [Cites] J Exp Med. 2001 Oct 15;194(8):1141-50 [11602642.001]
  • [Cites] Nature. 2003 Jan 23;421(6921):440-4 [12540919.001]
  • [Cites] Nature. 2003 Jan 23;421(6921):444-8 [12540920.001]
  • [Cites] Clin Immunol. 2003 Jun;107(3):186-97 [12804532.001]
  • [Cites] Science. 2003 Sep 5;301(5638):1374-7 [12920303.001]
  • [Cites] J Immunol. 2004 Apr 1;172(7):4624-9 [15034081.001]
  • [Cites] J Mol Biol. 1982 May 5;157(1):105-32 [7108955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Jul;79(13):4118-22 [6287467.001]
  • [Cites] Nature. 1983 Apr 14;302(5909):575-81 [6300689.001]
  • [Cites] Annu Rev Biochem. 1984;53:595-623 [6383201.001]
  • [Cites] Nature. 1984 Oct 25-31;311(5988):727-33 [6092962.001]
  • [Cites] Nature. 1984 Oct 25-31;311(5988):752-5 [6092963.001]
  • [Cites] J Exp Med. 1990 Jan 1;171(1):265-92 [2104919.001]
  • [Cites] EMBO J. 1990 Jul;9(7):2133-40 [2113468.001]
  • [Cites] J Immunol. 1991 Dec 15;147(12):4343-50 [1753104.001]
  • [Cites] J Immunol. 1992 Jul 1;149(1):222-9 [1607655.001]
  • [Cites] EMBO J. 1993 May;12(5):1819-26 [8491175.001]
  • [Cites] Science. 1993 Aug 27;261(5125):1171-5 [8356451.001]
  • [Cites] Mol Immunol. 1994 Feb;31(3):169-217 [8114766.001]
  • [Cites] J Immunol. 1996 Mar 15;156(6):2077-84 [8690895.001]
  • [Cites] J Clin Invest. 1996 Aug 1;98(3):600-3 [8698848.001]
  • [Cites] Immunol Rev. 1995 Dec;148:201-19 [8825288.001]
  • [Cites] FEBS Lett. 1996 Dec 9;399(1-2):1-8 [8980108.001]
  • [Cites] J Mol Biol. 1998 Jul 3;280(1):1-9 [9653027.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):7023-30 [9862739.001]
  • [Cites] FEBS Lett. 1999 Jul 16;455(1-2):188-97 [10428499.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):7773-80 [15944280.001]
  • [Cites] J Immunol. 2005 Nov 15;175(10):6624-32 [16272317.001]
  • [Cites] Nat Immunol. 2006 Mar;7(3):293-301 [16429139.001]
  • [Cites] J Exp Med. 2006 Jun 12;203(6):1567-78 [16754718.001]
  • [Cites] Eur J Immunol. 2007 Apr;37(4):1010-21 [17345580.001]
  • [Cites] J Virol. 2007 Sep;81(17):9331-8 [17567700.001]
  • [Cites] J Immunol. 2008 Dec 15;181(12):8416-24 [19050259.001]
  • [Cites] J Immunol. 2010 Jan 15;184(2):851-8 [20018621.001]
  • [Cites] Immunity. 2000 Jul;13(1):37-45 [10933393.001]
  • (PMID = 20956348.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Databank-accession-numbers] GENBANK/ HM154548/ HM154549/ HM154550/ HM154551/ HM154552/ HM154553/ HM154554/ HM154555/ HM154556/ HM154557/ HM154558/ HM154559/ HM154560/ HM154561/ HM154562/ HM154563/ HM154564/ HM154565/ HM154566/ HM154567/ HM154568/ HM154569/ HM154570/ HM154571/ HM154572/ HM154573/ HM154574/ HM154575/ HM154576/ HM154577/ HM154578/ HM154579/ HM154580/ HM154581/ HM154582/ HM154583/ HM154584/ HM154585/ HM154586/ HM154587/ HM154588/ HM154589/ HM154590/ HM154591/ HM154592/ HM154593/ HM154594/ HM154595/ HM154596/ HM154597/ HM154598/ HM154599/ HM154600/ HM154601/ HM154602/ HM154603/ HM154604/ HM154605/ HM154606/ HM154607/ HM154608/ HM154609/ HM154610/ HM154611/ HM154612/ HM154613/ HM154614/ HM154615/ HM154616/ HM154617/ HM154618/ HM154619/ HM154620/ HM154621/ HM154622/ HM154623/ HM154624/ HM154625/ HM154626/ HM154627/ HM154628/ HM154629/ HM154630/ HM154631/ HM154632/ HM154633/ HM154634/ HM154635/ HM154636/ HM154637/ HM154638/ HM154639/ HM154640/ HM154641/ HM154642/ HM154643/ HM154644/ HM154645/ HM154646/ HM154647/ HM154648/ HM154649/ HM154650/ HM154651/ HM154652/ HM154653/ HM154654/ HM154655/ HM154656/ HM154657/ HM154658/ HM154659/ HM154660/ HM154661/ HM154662/ HM154663/ HM154664/ HM154665/ HM154666/ HM154667/ HM154668/ HM154669/ HM154670/ HM154671/ HM154672/ HM154673/ HM154674/ HM154675/ HM154676/ HM154677/ HM154678/ HM154679/ HM154680/ HM154681/ HM154682/ HM154683/ HM154684/ HM154685/ HM154686/ HM154687/ HM154688/ HM154689/ HM154690/ HM154691/ HM154692/ HM154693/ HM154694/ HM154695/ HM154696/ HM154697/ HM154698/ HM154699/ HM154700/ HM154701/ HM154702/ HM154703/ HM154704/ HM154705/ HM154706/ HM154707/ HM154708/ HM154709/ HM154710/ HM154711/ HM154712/ HM154713/ HM154714/ HM154715/ HM154716/ HM154717/ HM154718/ HM154719/ HM154720/ HM154721/ HM154722/ HM154723/ HM154724/ HM154725/ HM154726/ HM154727/ HM154728/ HM154729/ HM154730/ HM154731/ HM154732/ HM154733/ HM154734/ HM154735/ HM154736/ HM154737/ HM154738/ HM154739/ HM154740/ HM154741/ HM154742/ HM154743/ HM154744/ HM154745/ HM154746/ HM154747/ HM154748/ HM154749/ HM154750/ HM154751/ HM154752/ HM154753/ HM154754/ HM154755/ HM154756/ HM154757/ HM154758/ HM154759/ HM154760/ HM154761/ HM154762/ HM154763/ HM154764/ HM154765/ HM154766/ HM154767/ HM154768/ HM154769/ HM154770/ HM154771/ HM154772/ HM154773/ HM154774/ HM154775/ HM154776/ HM154777/ HM154778/ HM154779/ HM154780/ HM154781/ HM154782/ HM154783/ HM154784/ HM154785/ HM154786/ HM154787/ HM154788/ HM154789/ HM154790/ HM154791/ HM154792/ HM154793/ HM154794/ HM154795/ HM154796/ HM154797/ HM154798/ HM154799/ HM154800/ HM154801/ HM154802/ HM154803/ HM154804/ HM154805/ HM154806/ HM154807/ HM154808/ HM154809/ HM154810/ HM154811/ HM154812/ HM154813/ HM154814/ HM154815/ HM154816/ HM154817/ HM154818/ HM154819/ HM154820/ HM154821/ HM154822/ HM154823/ HM154824/ HM154825/ HM154826/ HM154827/ HM154828/ HM154829/ HM154830/ HM154831/ HM154832/ HM154833/ HM154834/ HM154835/ HM154836/ HM154837/ HM154838/ HM154839/ HM154840/ HM154841/ HM154842/ HM154843/ HM154844/ HM154845/ HM154846/ HM154847/ HM154848/ HM154849/ HM154850/ HM154851/ HM154852/ HM154853/ HM154854/ HM154855/ HM154856/ HM154857/ HM154858/ HM154859/ HM154860/ HM154861/ HM154862/ HM154863/ HM154864/ HM154865/ HM154866/ HM154867/ HM154868/ HM154869/ HM154870/ HM154871/ HM154872/ HM154873/ HM154874/ HM154875/ HM154876/ HM154877/ HM154878/ HM154879/ HM154880/ HM154881/ HM154882/ HM154883/ HM154884/ HM154885/ HM154886/ HM154887/ HM154888/ HM154889/ HM154890/ HM154891/ HM154892/ HM154893/ HM154894/ HM154895/ HM154896/ HM154897/ HM154898/ HM154899/ HM154900/ HM154901/ HM154902/ HM154903/ HM154904/ HM154905/ HM154906/ HM154907/ HM154908/ HM154909/ HM154910/ HM154911/ HM154912/ HM154913/ HM154914/ HM154915/ HM154916/ HM154917/ HM154918/ HM154919/ HM154920/ HM154921/ HM154922/ HM154923/ HM154924/ HM154925/ HM154926/ HM154927/ HM154928/ HM154929/ HM154930/ HM154931/ HM154932/ HM154933/ HM154934/ HM154935/ HM154936
  • [Grant] United States / NIAID NIH HHS / AI / AI007051; United States / NIAID NIH HHS / AI / T32 AI007051; United States / NIAID NIH HHS / AI / AI048115; United States / NIAID NIH HHS / AI / AI078449; United States / NIAID NIH HHS / AI / R56 AI048115; United States / NIAID NIH HHS / AI / R21 AI078449; United States / NIAID NIH HHS / AI / R01 AI048115
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Complementarity Determining Regions; 0 / Immunoglobulin Heavy Chains; EC 2.7.7.31 / DNA Nucleotidylexotransferase
  • [Other-IDs] NLM/ NIHMS469908; NLM/ PMC3670101
  •  go-up   go-down


75. Melo JV, Barnes DJ: Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer; 2007 Jun;7(6):441-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic myeloid leukaemia as a model of disease evolution in human cancer.
  • Chronic myeloid leukaemia (CML) can be considered as a paradigm for neoplasias that evolve through a multi-step process.
  • If not cured at this stage, CML invariably progresses and transforms into an acute-type leukaemia undergoing a 'blast crisis'.
  • What mechanisms underlie this progression, and are they shared by other common cancers?
  • [MeSH-major] Blast Crisis. Disease Progression. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Models, Biological
  • [MeSH-minor] Animals. Cell Differentiation. Fusion Proteins, bcr-abl / physiology. Gene Expression Profiling. Genes, Tumor Suppressor / physiology. Genomic Instability. Humans. Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17522713.001).
  • [ISSN] 1474-175X
  • [Journal-full-title] Nature reviews. Cancer
  • [ISO-abbreviation] Nat. Rev. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Number-of-references] 153
  •  go-up   go-down


76. van Scherpenzeel Thim V, Remacle S, Picard J, Cornu G, Gofflot F, Rezsohazy R, Verellen-Dumoulin C: Mutation analysis of the HOX paralogous 4-13 genes in children with acute lymphoid malignancies: identification of a novel germline mutation of HOXD4 leading to a partial loss-of-function. Hum Mutat; 2005 Apr;25(4):384-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation analysis of the HOX paralogous 4-13 genes in children with acute lymphoid malignancies: identification of a novel germline mutation of HOXD4 leading to a partial loss-of-function.
  • We aimed to explore the possibility that germline alterations of HOX genes might be involved in childhood acute lymphoid malignancies.
  • A cohort of 86 children diagnosed with acute lymphoid malignancy was studied, 20 of them concurrently presenting a congenital anomaly of the skeleton.
  • Subsequently, we extended the HOX mutation screening to the other 66 children having a malignant lymphoproliferative disorder, but without skeletal defects.
  • While 13 changes were also observed in healthy controls, three variants were exclusively found in acute lymphoid malignancy cases.
  • These comprised the germline c.242A>T (p.Glu81Val) missense mutation of HOXD4, detected in two children diagnosed with acute lymphoblastic leukemia (ALL).
  • Furthermore, this mutation was found in association with other specific HOX variants of cluster D (2q31-q37), defining a unique haplotype.
  • Functional analysis of the murine Hoxd4 homolog revealed that mutant Hoxd4 protein had lower transcriptional activity than wild-type protein in vitro.
  • [MeSH-major] Germ-Line Mutation. Homeodomain Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Transcription Factors / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15776434.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 142981; RefSeq/ NM/ 014621
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HOXD1 protein, human; 0 / Homeodomain Proteins; 0 / Hoxd4 protein, mouse; 0 / Transcription Factors
  •  go-up   go-down


77. Holbert MA, Sikorski T, Carten J, Snowflack D, Hodawadekar S, Marmorstein R: The human monocytic leukemia zinc finger histone acetyltransferase domain contains DNA-binding activity implicated in chromatin targeting. J Biol Chem; 2007 Dec 14;282(50):36603-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The human monocytic leukemia zinc finger histone acetyltransferase domain contains DNA-binding activity implicated in chromatin targeting.
  • The human monocytic leukemia zinc finger (MOZ) protein is an essential transcriptional coactivator and histone acetyltransferase (HAT) that plays a primary role in the differentiation of erythroid and myeloid cells and is required to maintain hematopoietic stem cells.
  • Chromosomal translocations involving the HAT-encoded region are also associated with acute myeloid leukemia.
  • We find that the HAT domain contains a central region that is structurally and functionally conserved with the yeast MYST HAT protein Esa1, but contains more divergent N- and C-terminal regions harboring a TFIIIA-type zinc finger and helix-turn-helix DNA-binding motifs.
  • [MeSH-minor] Acetylation. Amino Acid Motifs / physiology. Animals. Cell Differentiation / physiology. Crystallography, X-Ray. DNA / chemistry. DNA / metabolism. Erythroid Precursor Cells / cytology. Erythroid Precursor Cells / metabolism. Histones / metabolism. Humans. Myeloid Progenitor Cells / cytology. Myeloid Progenitor Cells / metabolism. Nucleosomes / metabolism. Protein Binding / physiology. Protein Structure, Tertiary / physiology. Saccharomyces cerevisiae / cytology. Saccharomyces cerevisiae / metabolism. Saccharomyces cerevisiae Proteins / chemistry. Saccharomyces cerevisiae Proteins / metabolism. Structure-Activity Relationship. Translocation, Genetic / physiology. Xenopus laevis

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • The Lens. Cited by Patents in .
  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925393.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Databank-accession-numbers] PDB/ 2RC4
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM060293; United States / NIGMS NIH HHS / GM / GM60293
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones; 0 / Nucleosomes; 0 / Saccharomyces cerevisiae Proteins; 9007-49-2 / DNA; EC 2.3.1.48 / Esa1 protein, S cerevisiae; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / KAT6A protein, human
  •  go-up   go-down


78. Chakraborty J, Banerjee S, Ray P, Hossain DM, Bhattacharyya S, Adhikary A, Chattopadhyay S, Das T, Sa G: Gain of cellular adaptation due to prolonged p53 impairment leads to functional switchover from p53 to p73 during DNA damage in acute myeloid leukemia cells. J Biol Chem; 2010 Oct 22;285(43):33104-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gain of cellular adaptation due to prolonged p53 impairment leads to functional switchover from p53 to p73 during DNA damage in acute myeloid leukemia cells.
  • In wild-type p53-expressing cancer cells that were silenced for p53 for several generations, p73 was activated, whereas no such trend was observed when p53 was transiently silenced.
  • [MeSH-major] DNA Damage. DNA-Binding Proteins / metabolism. Leukemia, Myeloid, Acute / metabolism. Nuclear Proteins / metabolism. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Dec 13;18(53):7701-5 [10618710.001]
  • [Cites] FEBS Lett. 2009 May 6;583(9):1516-20 [19364507.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(4):1066-76 [11158294.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):199-207 [11252895.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):10641-5 [11152453.001]
  • [Cites] Cell Death Differ. 2001 Dec;8(12):1213-23 [11753569.001]
  • [Cites] Cell. 2002 Jan 25;108(2):153-64 [11832206.001]
  • [Cites] Cell Death Differ. 2002 Mar;9(3):229-30 [11859403.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3529-34 [11891335.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(8):2575-85 [11909952.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4715-27 [12101410.001]
  • [Cites] J Exp Med. 2002 Sep 16;196(6):765-80 [12235210.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2165-7 [12357376.001]
  • [Cites] Cancer Cell. 2003 May;3(5):421-9 [12781359.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(22):8161-71 [14585975.001]
  • [Cites] Cell Cycle. 2004 Jan;3(1):46-50 [14657665.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):8808-19 [14681223.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4401-6 [15070730.001]
  • [Cites] Genes Dev. 2004 Dec 15;18(24):3041-54 [15601819.001]
  • [Cites] Oncogene. 2005 Jan 27;24(5):938-44 [15558019.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):13213-9 [15634666.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):363-73 [15837625.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):20059-68 [15738001.001]
  • [Cites] Oncogene. 2006 Jun 15;25(25):3606-12 [16652159.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):362-70 [17210719.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):1955-60 [17404075.001]
  • [Cites] Mol Cell Biol. 2007 May;27(10):3868-80 [17353261.001]
  • [Cites] J Biol Chem. 2007 Jun 1;282(22):15954-64 [17392282.001]
  • [Cites] Oncogene. 2008 Jan 31;27(6):783-93 [17637740.001]
  • [Cites] Carcinogenesis. 2008 Jan;29(1):211-8 [17984115.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6302-7 [18424558.001]
  • [Cites] Oncogene. 2008 Oct 27;27(50):6507-21 [18955976.001]
  • [Cites] Drug Resist Updat. 2008 Aug-Oct;11(4-5):152-63 [18801697.001]
  • [Cites] Nat Rev Cancer. 2009 Feb;9(2):95-107 [19165225.001]
  • [Cites] Leukemia. 2009 Apr;23(4):656-63 [19151774.001]
  • [Cites] Nature. 2009 Apr 30;458(7242):1127-30 [19407794.001]
  • [Cites] Mutat Res. 1999 Dec 17;431(2):199-209 [10635987.001]
  • (PMID = 20675383.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / bcl-2-Associated X Protein; 0 / tumor suppressor protein p73; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / Checkpoint kinase 1
  • [Other-IDs] NLM/ PMC2963387
  •  go-up   go-down


79. Khan SQ, Kelly D, Quinn P, Davies JE, Ng LL: Cardiotrophin-1 predicts death or heart failure following acute myocardial infarction. J Card Fail; 2006 Oct;12(8):635-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiotrophin-1 predicts death or heart failure following acute myocardial infarction.
  • BACKGROUND: Cardiotrophin-1 (CT-1) is an important inflammatory cytokine; its presence has been documented in patients after acute myocardial infarction (AMI).
  • We sought to investigate this and compared it with N terminal pro-B-type natriuretic peptide (NT-proBNP), a marker of death or heart failure.

  • Genetic Alliance. consumer health - Myocardial infarction 1.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Card Fail. 2006 Oct;12(8):641-3 [17045184.001]
  • (PMID = 17045183.001).
  • [ISSN] 1532-8414
  • [Journal-full-title] Journal of cardiac failure
  • [ISO-abbreviation] J. Card. Fail.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cytokines; 0 / Peptide Fragments; 0 / cardiotrophin 1; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


80. Mansson R, Zandi S, Welinder E, Tsapogas P, Sakaguchi N, Bryder D, Sigvardsson M: Single-cell analysis of the common lymphoid progenitor compartment reveals functional and molecular heterogeneity. Blood; 2010 Apr 1;115(13):2601-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-cell analysis of the common lymphoid progenitor compartment reveals functional and molecular heterogeneity.
  • This allowed us to subfractionate common lymphoid progenitors and pre-pro-B (fraction A) cells into lambda5(-)Rag1(low), lambda5(-)Rag1(high), and lambda5(+)Rag1(high) cells.
  • Rag1(high) cells displayed reduced NK-cell potential with preserved capacity to generate B- and T-lineage cells, whereas the lambda5(+) cells were B-lineage restricted.
  • These data suggest that the classic common lymphoid progenitor compartment composes a mixture of cells with relatively restricted lineage potentials, thus opening new possibilities to investigate early hematopoiesis.
  • [MeSH-minor] Animals. Antigens, Ly / biosynthesis. Antigens, Ly / genetics. B-Cell-Specific Activator Protein / biosynthesis. B-Cell-Specific Activator Protein / genetics. Biomarkers. Cell Lineage. Cells, Cultured / cytology. Cells, Cultured / metabolism. Coculture Techniques. Flow Cytometry. GPI-Linked Proteins. Gene Expression Profiling. Gene Knock-In Techniques. Genes, Reporter. Homeodomain Proteins / genetics. Killer Cells, Natural / cytology. Lymphocyte Subsets / cytology. Lymphopoiesis. Mice. Mice, Transgenic. Reverse Transcriptase Polymerase Chain Reaction / methods. Trans-Activators / biosynthesis. Trans-Activators / genetics


81. Le QH, Thomas X, Ecochard R, Iwaz J, Lhéritier V, Michallet M, Fiere D: Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia. Eur J Haematol; 2006 Dec;77(6):471-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia.
  • Factors able to predict overall survival in adult patients with acute lymphoblastic leukaemia were assessed according to the period since initiation of the treatment using a Cox proportional hazards model.
  • From 1994 to 2002, 922 patients with acute lymphoblastic leukaemia (excluding French-American-British L3 subtype) were enrolled in a multicentre protocol and followed, with a mean follow up of 58 months.
  • Analyses of the initial (before 100 d) and the late phases were realised after stratification on the type of induction treatment and on the different treatment strategies respectively.
  • Determination of such factors is crucial to adapt postremission therapeutic strategies in acute lymphoblastic leukaemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16978239.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Denmark
  •  go-up   go-down


82. Yoon JS, Kim JY, Park HK, Kim ES, Ahn KS, Yoon SS, Cho CG, Kim BK, Lee YY: Antileukemic effect of a synthetic vitamin D3 analog, HY-11, with low potential to cause hypercalcemia. Int J Oncol; 2008 Feb;32(2):387-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3] is capable of inhibiting the proliferation of acute myelogenous leukemia (AML).
  • In addition, HY-11 enhanced the expression of TGF-beta1, TGF-beta receptor type I and II and vitamin D3 receptor (VDR).
  • In summary, HY-11 is a vitamin D3 analog that inhibited the proliferation of human AML cell line, HL-60, through induction of cell cycle arrest, triggering apoptosis as well as modulation of TGF-beta1 and its receptors.
  • In particular, HY-11 significantly increased the survival of mice that had myeloid leukemia without producing hypercalcemia.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cholecalciferol / analogs & derivatives. Cholecalciferol / chemistry. Hypercalcemia / prevention & control. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Animals. Calcium / metabolism. Cell Line, Tumor. Cell Proliferation. HL-60 Cells. Humans. Male. Mice. Mice, Inbred BALB C. Models, Chemical. Neoplasm Transplantation

  • Hazardous Substances Data Bank. CHOLECALCIFEROL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18202761.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / HY-11; 1C6V77QF41 / Cholecalciferol; SY7Q814VUP / Calcium
  •  go-up   go-down


83. Mielcarek M, Gooley T, Martin PJ, Chauncey TR, Young BA, Storb R, Torok-Storb B: Effects of race on survival after stem cell transplantation. Biol Blood Marrow Transplant; 2005 Mar;11(3):231-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of race on survival after stem cell transplantation.
  • Effects of race or ethnicity on survival after high-dose chemoradiation followed by stem cell transplantation (SCT) have not been thoroughly evaluated.
  • The greater mortality hazard among blacks persisted after controlling for donor type, pretransplantation risk category, patient age, donor/patient sex, and cytomegalovirus exposure (hazard ratio, 1.71; 95% confidence interval, 1.25-2.34).
  • SCT from both HLA-matched unrelated and HLA-identical sibling donors was associated with more severe acute graft-versus-host disease and higher nonrelapse mortality among blacks compared with whites.
  • Furthermore, blacks who received SCT for chronic myeloid leukemia had longer diagnosis-to-transplantation intervals than whites.
  • [MeSH-major] Continental Population Groups. Hematopoietic Stem Cell Transplantation / mortality

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744242.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Saumet A, Slimane MB, Lanotte M, Lawler J, Dubernard V: Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells. Blood; 2005 Jul 15;106(2):658-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells.
  • Here, we investigated potential antitumor action in an in vitro cell model for promyelocytic leukemia (NB4-LR1), resistant to retinoid maturation.
  • Purified soluble TSP-1 added to cultures induced a strong dose-dependent growth inhibition and a slowly developing maturation-independent cell death.
  • Recombinant fragments of TSP-1 allowed mapping of these activities to its type 3 repeat/C-terminal domain, features that are distinct from those of TSP-1 action on solid tumors, previously ascribed to the type 1 repeat domain.
  • Cell death in leukemia was characterized as a caspase-independent mechanism, without DNA fragmentation, but phosphatidylserine externalization followed by membrane permeabilization.
  • These results demonstrated a new domain-specific antitumoral activity of TSP-1 on a leukemia cell line, which extends TSP-1 therapeutic potential outside the area of vascularized solid tumors.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy. Thrombospondin 1 / pharmacology
  • [MeSH-minor] Amino Acid Sequence. Antigens, CD / metabolism. Antigens, CD47. Apoptosis / drug effects. Base Sequence. Caspases / metabolism. Cell Death / drug effects. Cell Division / drug effects. Cell Line, Tumor. Drug Resistance, Neoplasm. Humans. Integrin alphaVbeta3 / metabolism. Mitochondria / drug effects. Mitochondria / metabolism. Peptide Fragments / chemistry. Peptide Fragments / genetics. Peptide Fragments / pharmacology. Protein Structure, Tertiary. Reactive Oxygen Species / metabolism. Recombinant Proteins / chemistry. Recombinant Proteins / genetics. Recombinant Proteins / pharmacology. Tretinoin / pharmacology

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15784731.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD47; 0 / CD47 protein, human; 0 / Integrin alphaVbeta3; 0 / Peptide Fragments; 0 / Reactive Oxygen Species; 0 / Recombinant Proteins; 0 / Thrombospondin 1; 5688UTC01R / Tretinoin; EC 3.4.22.- / Caspases
  •  go-up   go-down


85. Manosroi A, Khositsuntiwong N, Götz F, Werner RG, Manosroi J: Transdermal enhancement through rat skin of luciferase plasmid DNA loaded in elastic nanovesicles. J Liposome Res; 2009;19(2):91-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transdermal enhancement through rat skin of luciferase plasmid DNA loaded in elastic nanovesicles.
  • Transdermal absorption of luciferase plasmid (pLuc) was enhanced by loading in elastic cationic liposomes and niosomes and the application of iontophoresis or the stratum corneum (SC) stripping method.
  • Cationic liposomes (DPPC/Chol/DDAB at a 1:1:1 molar ratio) and niosomes (Tween61/Chol/DDAB at a 1:1:0.5 molar ratio) were prepared by the freeze-dried empty liposomes method.
  • The elastic vesicles were prepared by hydrating the lipid or surfactant film by 25% of ethanol instead of distilled water.
  • Gel electrophoresis of all nanovesicles showed the 100% pLuc entrapment efficiency.
  • All nanovesicles loaded with pLuc showed larger vesicular sizes than the nonloaded vesicles of about 1.4 times for liposomes and 1.7 times for niosomes.
  • The nanovesicles loaded with pLuc demonstrated less positive zeta potential than the nonloaded vesicles.
  • The pLuc loaded in elastic vesicles kept at 4 +/- 2 and 27 +/- 2 degrees C for 8 weeks gave the remaining pLuc of about 70 and 60% for liposomes and 85 and 73% for niosomes, respectively.
  • For nonelastic vesicles kept at 4 +/- 2 degrees C, 56 and 61% of the remaining pLuc were observed for liposomes and niosomes, respectively, while at 27 +/- 2 degrees C, all pLuc were degraded.
  • The deformability indices of the elastic liposomes and niosomes loaded with the pLuc were 16.64 +/- 2.92 and 20.72 +/- 0.82, whereas the nonelastic vesicles gave 9.35 +/- 0.09 and 10.08 +/- 0.12, respectively.
  • Transdermal absorption through rat skin pretreated with SC stripping or treated with iontophoresis of pLuc loaded in nanovesicles by vertical Franz diffusion cells was investigated at 37 degrees C.
  • The cells were stopped and the skin and the receiving solution were withdrawn at 1, 3, and 6 hours and the pLuc contents in the stripped SC, whole skin (viable epidermis and dermis; VED), and the receiving solution were assayed by the modified gel electrophoresis and gel documentation.
  • Without the SC stripping technique or iontophoresis, the pLuc loaded and nonloaded in nonelastic cationic liposomes or niosomes were not found in SC, VED, and receiving solution.
  • The fluxes in the whole skin of pLuc loaded in nonelastic liposomes and niosomes with SC stripping and iontophoresis at 6 hours gave 2.73 +/- 0.46 and 3.83 +/- 0.73, and 7.01 +/- 1.22 and 9.60 +/- 1.31 g/cm(2)/h, respectively, while pLuc loaded in elastic liposomes and niosomes without the SC stripping and iontophoresis at 6 hours showed 2.79 +/- 0.09 and 2.84 +/- 0.04 g/cm(2)/h, respectively.
  • The pLuc loaded in elastic niosomes or in nonelastic niosomes with iontophoresis was found in the receiving solution with a higher amount than that loaded in elastic liposomes or nonelastic liposomes with iontophoresis.
  • The fluxes in the receiving solution of pLuc loaded in nonelastic liposomes and niosomes with iontophoresis at 6 hours were 6.71 +/- 0.31 and 8.82 +/- 0.28 g/cm(2)/h, respectively.
  • For elastic liposomes and niosomes, the fluxes of the loaded pLuc in the receiving solution were the same, at about 1.9 g/cm(2)/h.
  • Although pLuc loaded in nonelastic niosomes with iontophoresis gave the highest delivery of the plasmid in VED and receiving solution, a more promising applicable approach for gene delivery has been suggested to be the elastic niosomal systems, since no equipment is required.
  • [MeSH-major] Plasmids / metabolism. Skin / metabolism
  • [MeSH-minor] Administration, Cutaneous. Animals. Cations / metabolism. DNA / metabolism. Freeze Drying. Liposomes / metabolism. Luciferases / metabolism. Male. Quaternary Ammonium Compounds. Rats. Rats, Sprague-Dawley. Surface-Active Agents / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241277.001).
  • [ISSN] 1532-2394
  • [Journal-full-title] Journal of liposome research
  • [ISO-abbreviation] J Liposome Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cations; 0 / Liposomes; 0 / Quaternary Ammonium Compounds; 0 / Surface-Active Agents; 13146-86-6 / didodecyldimethylammonium; 9007-49-2 / DNA; EC 1.13.12.- / Luciferases
  •  go-up   go-down


86. Wu M, Sun XF, Xu ZM, Zhang XY, Li FR, Wang XG, Chen XL, Lin HQ, Wen HG, Sun X, Song TW: [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug;13(4):557-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
  • To test the European BIOMED-1 Concerted Action proposed technique to detect minimal residual disease (MRD) in the chinese patients with precursor-B-acute lymphoblastic leukemia (precursor-B-ALL) by triple-staining flow cytometry and to define both normal and aberrant phenotypic profiles of precursor B cells, a series of bone marrow samples, 35 from precursor-B-ALL (13 in newly diagnosed cases, 15 at the end of remission induction therapy and 7 at end of the consolidations), and 19 from normal controls, were immunophenotyped with the five triple-staining antibodies (TdT/CD10/CD19, CD10/CD20/CD19, CD34/CD38/CD19, CD34/CD22/CD19 and CD19/CD34/CD45) recom-mended by the BIOMED-1 using common flow cytometric protocols.
  • The results showed that three major CD19(+) cell subpopulations were identified in the normal controls, representing three consecutive maturation stages.
  • The subpopulations in the precursor-B-ALL cases disappeared and were replaced with a great number of luekemic cells which had different characteristics of phenotypes, and then they reappeared with almost same characteristics as the normal CD19(+) cells after the patients achieved complete remission.
  • When the five triple-staining antibody combinations were used, the phenotypic aberrancies could be identified in 12/13 (92.3%) cases with newly diagnosed precursor-B-ALL, at least one triple-labeling per case at the level of 0.01% or more.
  • At the end of remission induction, the phenotypic aberrancies could be detected in 5/15 (33.3%), of which, 3/8 (37.5%) cases with the leukemic phenotypes detected both at the newly diagnosis and at the end of induction.
  • It is concluded that the flow cytometric detection of precursor-B-ALL-MRD proposed by BIOMED-1 Concerted Action were well realized in this study.
  • The one precursor-B-ALL cell can be effectively detected out of 10(4) normal bone marrow cells.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16129033.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


87. Vallera DA, Oh S, Chen H, Shu Y, Frankel AE: Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases. Mol Cancer Ther; 2010 Jun;9(6):1872-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.
  • The aims were to reduce toxin immunogenicity using mutagenesis, measure the ability of mutated drug to elicit antitoxin antibody responses, and show that mutated drug was effective against systemic B-cell lymphoma in vivo.
  • Site-specific mutagenesis was used to mutate amino acids in seven key epitopic toxin regions that dictate B-cell generation of neutralizing antitoxin antibodies.
  • Finally, a powerful genetically altered luciferase xenograft model was used that could be imaged in real time to determine the effect on systemic malignant human B-cell lymphoma, Raji-luc.
  • Patient B-lineage acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia, and B lymphoma were high in CD22 and CD19 expression.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8548-53 [10890891.001]
  • [Cites] Cell. 1987 Mar 13;48(5):899-907 [3545499.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):995-1002 [11948105.001]
  • [Cites] Expert Opin Biol Ther. 2002 Dec;2(8):785-91 [12517258.001]
  • [Cites] Mol Cancer Ther. 2003 Dec;2(12):1341-50 [14707275.001]
  • [Cites] Cancer Res. 1968 Jul;28(7):1300-10 [4174339.001]
  • [Cites] Int J Cancer. 1978 Feb 15;21(2):166-70 [203546.001]
  • [Cites] Nature. 1989 Jun 1;339(6223):394-7 [2498664.001]
  • [Cites] Protein Eng. 1993 Nov;6(8):989-95 [8309948.001]
  • [Cites] Blood. 1994 Mar 1;83(5):1329-36 [7509655.001]
  • [Cites] Br J Cancer. 1995 Dec;72(6):1373-9 [8519647.001]
  • [Cites] Leukemia. 1996 Jun;10(6):937-42 [8667648.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1188-97 [8695836.001]
  • [Cites] J Cell Biol. 1996 Sep;134(6):1411-25 [8830771.001]
  • [Cites] Cell. 1997 Jul 25;90(2):335-49 [9244307.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2364-75 [9310487.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):968-75 [9500458.001]
  • [Cites] J Cell Biol. 1998 Nov 2;143(3):601-12 [9813083.001]
  • [Cites] Lancet. 1964 Feb 1;1(7327):238-40 [14086209.001]
  • [Cites] Leuk Res. 2005 Mar;29(3):331-41 [15661270.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3879-88 [15897589.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6719-29 [16061911.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8822-34 [17142785.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):3058-67 [17505009.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5144-9 [17785569.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4919-28 [17878392.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6486-93 [17975161.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11311-6 [18678888.001]
  • [Cites] Expert Opin Biol Ther. 2009 Jan;9(1):79-95 [19063695.001]
  • [Cites] Leuk Res. 2009 Sep;33(9):1233-42 [19327829.001]
  • [Cites] Br J Cancer. 2009 Oct 6;101(7):1114-23 [19755995.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6137-47 [19789305.001]
  • [Cites] Adv Drug Deliv Rev. 2009 Sep 30;61(11):977-85 [19679153.001]
  • [Cites] J Neurooncol. 2009 Dec;95(3):331-42 [19517064.001]
  • [Cites] EMBO J. 2009 Dec 2;28(23):3730-44 [19851281.001]
  • [Cites] Pancreas. 2010 Aug;39(6):913-22 [20182395.001]
  • [Cites] Blood. 1984 Jun;63(6):1424-33 [6609729.001]
  • [Cites] J Exp Med. 1986 Feb 1;163(2):347-68 [3511171.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):376-88 [11208829.001]
  • (PMID = 20530709.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108637; United States / NCI NIH HHS / CA / R01 CA082154; United States / NCI NIH HHS / CA / CA036725-25; United States / NCI NIH HHS / CA / CA108637-05; United States / NCI NIH HHS / CA / R01 CA036725; United States / NCI NIH HHS / CA / R01-CA36725; United States / NCI NIH HHS / CA / R01-CA082154; United States / NCI NIH HHS / CA / R01 CA108637-05; United States / NCI NIH HHS / CA / R01 CA036725-25
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antigens, CD19; 0 / Bacterial Toxins; 0 / Exotoxins; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / Virulence Factors; EC 2.4.2.- / ADP Ribose Transferases; EC 2.4.2.31 / toxA protein, Pseudomonas aeruginosa
  • [Other-IDs] NLM/ NIHMS198461; NLM/ PMC2884080
  •  go-up   go-down


88. Campino S, Forton J, Auburn S, Fry A, Diakite M, Richardson A, Hull J, Jallow M, Sisay-Joof F, Pinder M, Molyneux ME, Taylor TE, Rockett K, Clark TG, Kwiatkowski DP: TLR9 polymorphisms in African populations: no association with severe malaria, but evidence of cis-variants acting on gene expression. Malar J; 2009 Mar 13;8:44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • First, an association study of four common single nucleotide polymorphisms was performed on both family- and population-based studies from Malawian and Gambian populations (n>6000 individual).
  • For this work, an allele specific expression (ASE) assay on a panel of HapMap cell lines was carried out.
  • Using an allele specific expression assay it was observed that TLR9 expression is affected by cis-acting variants, these results were replicated in a second experiment using biological replicates.
  • This analysis considered all common variants in the region, but it is remains possible that there are rare variants with association signals.

  • Genetic Alliance. consumer health - Malaria.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Jun 1;101(11):4500-4 [12560217.001]
  • [Cites] PLoS Genet. 2007 Jun;3(6):e99 [17571926.001]
  • [Cites] Genet Epidemiol. 2004 Apr;26(3):186-205 [15022206.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):394-9 [15052269.001]
  • [Cites] J Immunol. 2004 Apr 15;172(8):4926-33 [15067072.001]
  • [Cites] Nature. 2004 Aug 12;430(7001):743-7 [15269782.001]
  • [Cites] Science. 2004 Oct 22;306(5696):647-50 [15499010.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5847-51 [1631067.001]
  • [Cites] Am J Hum Genet. 1993 Mar;52(3):506-16 [8447318.001]
  • [Cites] N Engl J Med. 1995 May 25;332(21):1399-404 [7723795.001]
  • [Cites] J Exp Med. 2005 Jan 3;201(1):19-25 [15630134.001]
  • [Cites] Nat Genet. 2007 Oct;39(10):1217-24 [17873874.001]
  • [Cites] Nat Genet. 2007 Oct;39(10):1208-16 [17873875.001]
  • [Cites] J Immunol. 2008 Feb 15;180(4):2496-503 [18250459.001]
  • [Cites] J Infect Dis. 2008 Sep 1;198(5):772-80 [18662133.001]
  • [Cites] Hum Hered. 2009;67(1):26-37 [18931507.001]
  • [Cites] PLoS One. 2008;3(12):e4105 [19116668.001]
  • [Cites] Anal Biochem. 2005 Apr 15;339(2):231-41 [15797563.001]
  • [Cites] Environ Microbiol. 2005 Jul;7(7):1024-8 [15946299.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1365-9 [16251966.001]
  • [Cites] Hum Mol Genet. 2005 Dec 15;14(24):3963-71 [16301213.001]
  • [Cites] PLoS Genet. 2005 Dec;1(6):e78 [16362079.001]
  • [Cites] J Infect Dis. 2006 Jul 15;194(2):184-8 [16779724.001]
  • [Cites] Am J Hum Genet. 2006 Sep;79(3):539-43 [16909391.001]
  • [Cites] Genome Res. 2007 Jan;17(1):82-7 [17135570.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):1919-24 [17261807.001]
  • [Cites] J Commun Dis. 2006 Mar;38(3):230-45 [17373355.001]
  • [Cites] Am J Pathol. 2007 Aug;171(2):548-59 [17600128.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):789-96 [14685227.001]
  • (PMID = 19284650.001).
  • [ISSN] 1475-2875
  • [Journal-full-title] Malaria journal
  • [ISO-abbreviation] Malar. J.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0600230; United Kingdom / Medical Research Council / / G19/9; United Kingdom / Medical Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Toll-Like Receptor 9
  • [Other-IDs] NLM/ PMC2660361
  •  go-up   go-down


89. Kawabata Y, Hirokawa M, Saitoh Y, Kosugi S, Yoshioka T, Fujishima M, Fujishima N, Kameoka Y, Saitoh H, Kume M, Takahashi N, Sawada K: Late-onset fatal Epstein-Barr virus-associated hemophagocytic syndrome following cord blood cell transplantation for adult acute lymphoblastic leukemia. Int J Hematol; 2006 Dec;84(5):445-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late-onset fatal Epstein-Barr virus-associated hemophagocytic syndrome following cord blood cell transplantation for adult acute lymphoblastic leukemia.
  • A 43-year-old Japanese woman underwent unrelated cord blood transplantation (CBT) during remission for acute lymphoblastic leukemia with t(4; 11)(q21;q23).
  • The posttransplantation clinical course was mostly uneventful, and the leukemia remained in remission.
  • Although the patient showed complete donor-type hematopoiesis, the titer of viral capsid antigen immunoglobulin G was low, and the results of a test for EBV nuclear antigen were negative.
  • [MeSH-major] Epstein-Barr Virus Infections. Hemorrhage. Herpesvirus 4, Human. Lymphohistiocytosis, Hemophagocytic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


90. Makki MS, Heinzel T, Englert C: TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels. Nucleic Acids Res; 2008 Jul;36(12):4067-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During embryogenesis, WT1 is expressed in a time- and tissue-specific manner in various organs including gonads and kidney but also in the hematopoietic system.
  • Although widely regarded as a tumor suppressor gene, wild-type WT1 is overexpressed in a variety of hematologic malignancies, most notably in acute lymphoblastic leukemia as well as myelodysplastic syndromes.
  • We show here that histone deacetylase inhibitors like Trichostatin A (TSA) can promptly and dramatically downregulate Wt1 expression levels in different cell lines.
  • [MeSH-minor] Animals. Cell Line. Cell Line, Tumor. Humans. Mice. Proteasome Endopeptidase Complex / metabolism. Transcription, Genetic. Ubiquitin-Conjugating Enzymes / metabolism